[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 785
1. Vianello F, Papeta N, Chen T, Kraft P, White N, Hart WK, Kircher MF, Swart E, Rhee S, Palù G, Irimia D, Toner M, Weissleder R, Poznansky MC: Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol; 2006 Mar 1;176(5):2902-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
  • Murine B16/OVA melanoma cells (H2b) were engineered to constitutively express CXCL12.
  • Immunization of C57BL/6 mice with B16/OVA cells lead to destruction of B16/OVA tumors expressing no or low levels of CXCL12 but not tumors expressing high levels of the chemokine.
  • Early recruitment of adoptively transferred OVA-specific CTL into B16/OVA tumors expressing high levels of CXCL12 was significantly reduced in comparison to B16/OVA tumors, and this reduction was reversed when tumor-specific CTLs were pretreated with the specific CXCR4 antagonist, AMD3100.
  • Memory OVA-specific CD8+ T cells demonstrated antitumor activity against B16/OVA tumors but not B16/OVA.CXCL12-high tumors.
  • Expression of high levels of CXCL12 by B16/OVA cells significantly reduced CTL colocalization with and killing of target cells in vitro in a CXCR4-dependent manner.
  • The repulsion of tumor Ag-specific T cells away from melanomas expressing CXCL12 confirms the chemorepellent activity of high concentrations of CXCL12 and may represent a novel mechanism by which certain tumors evade the immune system.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2006 May 1;176(9):5683
  • (PMID = 16493048.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / P41 EB002503; United States / NIAID NIH HHS / AI / R01 AI49757; United States / NIAID NIH HHS / AI / R21 AI49858
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Epitopes, T-Lymphocyte; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, CCR5; 0 / Receptors, CXCR4; 9006-59-1 / Ovalbumin
  •  go-up   go-down


2. Curran MA, Montalvo W, Yagita H, Allison JP: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A; 2010 Mar 2;107(9):4275-80
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
  • Vaccination with irradiated B16 melanoma cells expressing either GM-CSF (Gvax) or Flt3-ligand (Fvax) combined with antibody blockade of the negative T-cell costimulatory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) promotes rejection of preimplanted tumors.
  • Here, we show that the combination of CTLA-4 and PD-1 blockade is more than twice as effective as either alone in promoting the rejection of B16 melanomas in conjunction with Fvax.
  • Combination blockade also synergistically increases Teff-to-myeloid-derived suppressor cell ratios within B16 melanomas.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3239-46 [10866317.001]
  • [Cites] Immunol Rev. 2008 Aug;224:141-65 [18759925.001]
  • [Cites] J Exp Med. 2003 Apr 7;197(7):875-83 [12668647.001]
  • [Cites] J Exp Med. 2004 Jun 7;199(11):1479-89 [15184501.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):721-30 [1847722.001]
  • [Cites] Immunity. 1995 Nov;3(5):541-7 [7584144.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • [Cites] Immunity. 1999 Aug;11(2):141-51 [10485649.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1586-92 [16034097.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9543-53 [16227604.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3321-9 [16517699.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1935-45 [16778987.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1902-13 [17557120.001]
  • [Cites] Int Immunol. 2007 Jul;19(7):813-24 [17606980.001]
  • [Cites] Immunity. 2007 Jul;27(1):111-22 [17629517.001]
  • [Cites] Scand J Immunol. 2007 Oct;66(4):435-40 [17850588.001]
  • [Cites] Eur J Immunol. 2007 Dec;37(12):3445-54 [18034419.001]
  • [Cites] Nat Rev Immunol. 2008 Feb;8(2):153-60 [18219311.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3044-51 [18483370.001]
  • [Cites] Cancer Immunol Immunother. 2009 May;58(5):687-97 [18828017.001]
  • [Cites] Nat Rev Immunol. 2009 Mar;9(3):162-74 [19197294.001]
  • [Cites] PLoS Pathog. 2009 Feb;5(2):e1000313 [19247441.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1623-34 [19208793.001]
  • [Cites] J Exp Med. 2009 Aug 3;206(8):1717-25 [19581407.001]
  • [Cites] Int Immunol. 2009 Sep;21(9):1065-77 [19651643.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7747-55 [19738077.001]
  • [Cites] Nat Immunol. 2009 Nov;10(11):1185-92 [19783989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 [12218188.001]
  • (PMID = 20160101.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Cancer Vaccines; 0 / Pdcd1 protein, mouse; 0 / Programmed Cell Death 1 Receptor; 82115-62-6 / Interferon-gamma; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Gzmb protein, mouse
  • [Other-IDs] NLM/ PMC2840093
  •  go-up   go-down


3. Stanford MM, Shaban M, Barrett JW, Werden SJ, Gilbert PA, Bondy-Denomy J, Mackenzie L, Graham KC, Chambers AF, McFadden G: Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther; 2008 Jan;16(1):52-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have found that several mouse tumor cell lines, including B16 melanomas, are permissive to MV infection.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / therapy. Melanoma, Experimental / therapy. Melanoma, Experimental / virology. Myxoma virus. Oncolytic Virotherapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998900.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI080607; United States / NCI NIH HHS / CA / R01 CA138541
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 0 / Antibiotics, Antineoplastic; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS673028; NLM/ PMC4376281
  •  go-up   go-down


Advertisement
4. Nguyen Huu S, Oster M, Avril MF, Boitier F, Mortier L, Richard MA, Kerob D, Maubec E, Souteyrand P, Moguelet P, Khosrotehrani K, Aractingi S: Fetal microchimeric cells participate in tumour angiogenesis in melanomas occurring during pregnancy. Am J Pathol; 2009 Feb;174(2):630-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal microchimeric cells participate in tumour angiogenesis in melanomas occurring during pregnancy.
  • Melanoma is a major malignancy in younger individuals that accounts for 8% of all neoplasias associated with gestation.
  • To understand the relationship between melanoma and pregnancy, we analyzed these tumors in both humans and mice.
  • Fetal cells were detected in 63% of human primary melanomas versus 12% in nevi during pregnancy (P = 0.034) and in 57% of B16 melanomas in pregnant mice but never in normal skin (P = 0.000022).
  • In conclusion, we show that melanomas during pregnancy frequently harbor fetal cells that have an endothelial phenotype.
  • [MeSH-major] Chimerism. Melanoma / pathology. Neovascularization, Pathologic / pathology. Pregnancy. Pregnancy Complications, Neoplastic / pathology. Skin Neoplasms / pathology


5. Ortiz R, Prados J, Melguizo C, Rama AR, Segura A, Rodríguez-Serrano F, Boulaiz H, Hita F, Martinez-Amat A, Madeddu R, Ramos JL, Aranega A: The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo. J Mol Med (Berl); 2009 Sep;87(9):899-911
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.
  • Novel treatment modalities, including gene therapy, are needed for patients with advanced melanoma.
  • To evaluate whether this E gene has a cytotoxic impact on melanoma cells in vitro and in vivo, and could therefore be used as a new therapeutic strategy for this tumor type, we selected the B16-F10 murine melanoma cell line as a model.
  • We used a nonviral gene delivery approach (pcDNA3.1/E plasmid) to study the inhibition of melanoma cells' proliferation in vitro and direct intratumoral injection of pcDNA3.1/E complexed with jetPEI to deliver E cDNA to rapidly growing murine melanomas, and found that the E gene has both a strong antiproliferative effect in B16-F10 cells in vitro and induces an efficient decrease in melanoma tumor volume in vivo (90% in 15 days).
  • Interestingly, the GFP-E fusion protein expressed in melanoma cells was located in the mitochondria.
  • These results show that E gene expression in melanoma cells has an extraordinary antitumor effect, which means it may be a new candidate for an effective strategy for melanoma treatment.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. DNA, Viral / administration & dosage. Melanoma, Experimental. Mice. Mitochondria / drug effects. Mitochondrial Proteins / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2008 Aug;159(2):370-8 [18565182.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):553-60 [18402522.001]
  • [Cites] FASEB J. 2008 Dec;22(12):4272-80 [18716030.001]
  • [Cites] Exp Dermatol. 2008 Jan;17(1):1-11 [18095940.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):191-201 [18502571.001]
  • [Cites] J Gene Med. 2008 Feb;10(2):113-22 [18076132.001]
  • [Cites] J Gene Med. 2006 Feb;8(2):229-41 [16170834.001]
  • [Cites] Int J Oncol. 2008 Jun;32(6):1245-51 [18497986.001]
  • [Cites] Cancer Gene Ther. 2007 Feb;14(2):165-73 [17008932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4297-302 [10760296.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1610-9 [16818521.001]
  • [Cites] Rev Recent Clin Trials. 2006 Sep;1(3):217-35 [18473975.001]
  • [Cites] Curr Opin Mol Ther. 2004 Aug;6(4):421-35 [15468601.001]
  • [Cites] J Virol. 1982 Dec;44(3):993-1002 [6294347.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):1005-12 [18507048.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1551-60 [15742333.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):117-27 [15015777.001]
  • [Cites] Bioorg Med Chem. 2008 May 1;16(9):5295-302 [18359635.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):121-7 [18575757.001]
  • [Cites] FEBS J. 2007 Sep;274(18):4825-36 [17714513.001]
  • [Cites] Eur J Biochem. 2003 Apr;270(8):1599-618 [12694174.001]
  • [Cites] FEMS Microbiol Lett. 1998 Jul 1;164(1):149-57 [9675861.001]
  • [Cites] Microbiology. 2006 Oct;152(Pt 10):2959-67 [17005977.001]
  • [Cites] Mol Ther. 2006 Nov;14(5):647-55 [16950655.001]
  • [Cites] Gene Ther. 2007 Jul;14(13):998-1009 [17443216.001]
  • [Cites] Cell Res. 2007 Dec;17(12):976-84 [18071367.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1584-90 [19039293.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):326-34 [10690507.001]
  • [Cites] J Gene Med. 2003 Mar;5(3):219-31 [12666188.001]
  • [Cites] J Invest Dermatol. 2005 Jan;124(1):221-8 [15654977.001]
  • [Cites] Mol Biotechnol. 2008 May;39(1):39-48 [18092145.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):445-9 [17245336.001]
  • [Cites] Cancer Gene Ther. 2006 Sep;13(9):845-55 [16710344.001]
  • [Cites] Arch Dermatol Res. 2001 Nov;293(10):484-90 [11820724.001]
  • (PMID = 19579018.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / Mitochondrial Proteins; 0 / Repressor Proteins; 0 / Viral Regulatory and Accessory Proteins; 0 / phage repressor proteins
  •  go-up   go-down


6. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ: Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med; 2005 Jan 3;201(1):139-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, in vivo administration of IL-21 in combination with IL-15 boosted antigen-specific CD8+ T cell numbers and resulted in a cooperative effect on tumor regression, with apparent cures of large, established B16 melanomas.
  • [MeSH-major] CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. Interleukin-15 / pharmacology. Interleukins / pharmacology. Melanoma, Experimental / therapy


7. Williams P, Rafei M, Bouchentouf M, Raven J, Yuan S, Cuerquis J, Forner KA, Birman E, Galipeau J: A Fusion of GMCSF and IL-21 Initiates Hypersignaling Through the IL-21Rα Chain With Immune Activating and Tumoricidal Effects In Vivo. Mol Ther; 2010 Jul;18(7):1293-1301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B16 melanoma cells gene-enhanced to produce GIFT-21 were immune rejected by syngeneic C57Bl/6 mice comparable to the effect of IL-21 alone.
  • However, a significant GIFT-21-driven survival advantage was seen when NOD-SCID mice were implanted with GIFT-21-secreting B16 cells, consistent with a meaningful role of macrophages in tumor rejection.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178447.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR: Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood; 2009 Nov 5;114(19):4310-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In different combinations, BM contribution was detected in ischemic retinas and, to a lesser extent, Lewis lung carcinoma cells, whereas B16 melanomas showed little to no BM contribution.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2007 Jul;28(7):299-307 [17560169.001]
  • [Cites] Genes Dev. 2007 Jun 15;21(12):1546-58 [17575055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6620-5 [18443294.001]
  • [Cites] Cell. 2008 Jun 13;133(6):994-1005 [18555776.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):923-34 [18604199.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Feb;69(2):108-24 [18768327.001]
  • [Cites] Stem Cells. 2009 Feb;27(2):457-66 [19038791.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jul;6(7):395-404 [19424102.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4372-8 [11035074.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Nat Med. 2002 Jun;8(6):607-12 [12042812.001]
  • [Cites] Nat Med. 2003 Jun;9(6):789-95 [12740570.001]
  • [Cites] Blood. 2004 Jan 1;103(1):133-5 [12969964.001]
  • [Cites] Circ Res. 2004 Feb 6;94(2):230-8 [14656934.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1769-77 [15187022.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] Blood. 1998 Jul 15;92(2):362-7 [9657732.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):86-93 [15630447.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1916-22 [15546953.001]
  • [Cites] Nat Med. 2005 Mar;11(3):261-2 [15723071.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):2890-9 [16116175.001]
  • [Cites] Stem Cells Dev. 2005 Oct;14(5):478-86 [16305333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18111-6 [16326806.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2774-6 [16339405.001]
  • [Cites] Blood. 2006 May 1;107(9):3546-54 [16391016.001]
  • [Cites] Nat Med. 2006 May;12(5):557-67 [16648859.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):374-82; discussion 374-82 [16883178.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1801-9 [17053059.001]
  • [Cites] Genes Dev. 2008 Mar 1;22(5):559-74 [18316475.001]
  • (PMID = 19717647.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK067359; United States / NCI NIH HHS / CA / CA084408; United States / NCI NIH HHS / CA / CA089655; United States / NHLBI NIH HHS / HL / R01 HL075258; United States / NCI NIH HHS / CA / R01 CA089655; United States / NHLBI NIH HHS / HL / R01 HL070738; United States / NCI NIH HHS / CA / R01 CA084408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCR4 protein, mouse; 0 / Chemokine CXCL12; 0 / Cxcl12 protein, mouse; 0 / Receptors, CXCR4
  • [Other-IDs] NLM/ PMC2774559
  •  go-up   go-down


9. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM: An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol; 2006 Dec;24(12):1581-90
eagle-i research resources. PMID 17143278 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • M(F)-DeltaAkt-transduced DCs enhanced T-cell proliferation, activation and long-term memory responses, enabling eradication of large pre-established lymphomas and aggressive B16 melanomas.
  • [MeSH-minor] Animals. Biosynthetic Pathways. Carboxylic Ester Hydrolases / metabolism. Cell Differentiation. Humans. Immunotherapy / methods. Lymphoma / therapy. Melanoma / therapy. Mice. Mice, Knockout. Mitochondrial Proteins / metabolism. Skin Neoplasms / therapy


10. Dietrich A, Becherer L, Brinckmann U, Hauss J, Liebert UG, Gütz A, Aust G: Particle-mediated cytokine gene therapy leads to antitumor and antimetastatic effects in mouse carcinoma models. Cancer Biother Radiopharm; 2006 Aug;21(4):333-41
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Lewis lung carcinomas and B16 melanomas, intradermally established on C57/Bl6 mice, were shot using a gene gun every 4th day with a combination of plasmids.
  • [MeSH-major] Carcinoma, Lewis Lung / therapy. Cytokines / genetics. Genetic Therapy / methods. Melanoma, Experimental / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999599.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


11. Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN: Immune rejection of mouse tumors expressing mutated self. Cancer Res; 2009 Apr 15;69(8):3545-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address these questions, a mutated self-antigen, designated tyrosinase-related protein 1 (Tyrp1)-WM, derived from Tyrp1 was expressed in the poorly immunogenic, spontaneously arising B16 melanoma and the immunogenic, chemically induced LiHa fibrosarcoma.
  • B16 melanomas expressing Tyrp1-WM induced minimal T-cell responses, and no tumor immunity was detected.
  • These results show that B16 tumors expressing mutations that generate strongly immunogenic epitopes naturally induce T-cell responses, which are insufficient to reject tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2004 Mar;34(3):613-22 [14991590.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1553-61 [9802967.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7306-14 [15187106.001]
  • [Cites] Immunogenetics. 2004 Sep;56(6):405-19 [15349703.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):5008-20 [15470044.001]
  • [Cites] Br J Cancer. 1976 Mar;33(3):241-59 [773395.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1295-311 [6232335.001]
  • [Cites] Cell. 1989 Jul 28;58(2):293-303 [2568889.001]
  • [Cites] J Exp Med. 1990 Apr 1;171(4):1375-80 [2324688.001]
  • [Cites] Exp Cell Res. 1991 Oct;196(2):233-40 [1832641.001]
  • [Cites] Nature. 1994 May 5;369(6475):67-71 [8164742.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1599-607 [7964448.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):324-31 [9540969.001]
  • [Cites] Eur J Immunol. 1999 Feb;29(2):592-601 [10064075.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):885-91 [16186187.001]
  • [Cites] Nat Med. 2006 Feb;12(2):198-206 [16444264.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4904-12 [16651447.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1382-90 [16614758.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6434-42 [16709800.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2587-90 [17016554.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2777-90 [17016559.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42 [17108085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18033-4 [17116890.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):889-92 [18245491.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • [Cites] Immunity. 2000 Oct;13(4):529-38 [11070171.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4078-83 [11358829.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):135-42 [11812990.001]
  • [Cites] Immunity. 2002 Feb;16(2):311-23 [11869690.001]
  • [Cites] J Mol Biol. 2003 Feb 28;326(4):1157-74 [12589760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15059-64 [14608036.001]
  • [Cites] Adv Cancer Res. 2003;90:157-77 [14710950.001]
  • [Cites] Immunity. 1995 Jan;2(1):45-59 [7600302.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):113-9 [7615964.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1281-4 [7652577.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):695-705 [9034148.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):932-6 [9185691.001]
  • [Cites] J Invest Dermatol. 1997 Dec;109(6):788-95 [9406822.001]
  • [Cites] J Immunol. 2004 May 15;172(10):5823-7 [15128759.001]
  • (PMID = 19351857.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] None / None / / R01 CA056821-16; United States / NCI NIH HHS / CA / P01 CA033049-24; United States / NCI NIH HHS / CA / R01 CA056821-16; United States / NCI NIH HHS / CA / CA033049-24; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA56821; United States / NCI NIH HHS / CA / P01 CA059350; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCI NIH HHS / CA / P01 CA59350; United States / NCI NIH HHS / CA / P01 CA33049
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Epitopes, T-Lymphocyte; 0 / Membrane Glycoproteins; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse
  • [Other-IDs] NLM/ NIHMS117220; NLM/ PMC2767208
  •  go-up   go-down


12. Arora A, Su G, Mathiowitz E, Reineke J, Chang AE, Sabel MS: Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity. J Surg Oncol; 2006 Oct 1;94(5):403-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: C57BL6 mice with established B16 melanomas underwent a single intralesional injection of IL-12, TNF-alpha or GM-CSF PLAM, alone or in combination.
  • Adjuvant therapy, using irradiated B16 cells in combination with equivalent doses of IL-12 and TNF-alpha, failed to generate a similar T-cell response or prevent re-challenge.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy, Adoptive. Interleukin-12 / administration & dosage. Melanoma, Experimental / immunology. Melanoma, Experimental / therapy. Tumor Necrosis Factor-alpha / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16967445.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102602-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Polymers; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12; 26100-51-6 / poly(lactic acid); 33X04XA5AT / Lactic Acid; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


13. Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y, Cutter E, Lieber A, Hellström I, Hellström KE: Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res; 2007 Mar 1;67(5):2339-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that wild-type (WT) cells from the K1735 melanoma (K1735-WT) are rejected following vaccination with cells (K1735-1D8) transfected to express scFv from the anti-CD137 monoclonal antibody 1D8, and that CD4(+) T cells and natural killer (NK) cells are needed for this rejection.
  • We further show that the percentage of NK cells was higher in B16-1D8 melanomas expressing anti-CD137 scFv than in the WT tumors and that the percentage of FoxP3(+) cells was lower.
  • Inhibition of WT tumor cells by tumor cells transfected to express anti-CD137 scFv was shown also with the TC1 carcinoma and B16 melanoma.
  • Furthermore, injection of an adenovirus vector, Ad-1D8, which encodes anti-CD137 scFv into established B16 melanomas, significantly prolonged the survival of tumor-bearing mice and could induce regression.
  • [MeSH-major] Antigens, CD137 / immunology. Immunoglobulin Fragments / therapeutic use. Melanoma, Experimental / therapy. Recombinant Fusion Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332366.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01 112073
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD137; 0 / Immunoglobulin Fragments; 0 / Lymphokines; 0 / Recombinant Fusion Proteins; 0 / immunoglobulin Fv
  •  go-up   go-down


14. Dietrich A, Stockmar C, Aust G, Endesfelder S, Guetz A, Sack U, Schoenfelder M, Hauss J: Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model. J Cancer Res Clin Oncol; 2006 Jun;132(6):379-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pre-established B16 melanomas on C57/Bl6 mice were surgically removed; mice were vaccinated intraoperatively with B16 cells transfected with an IL-12-encoding pRSC construct, the empty plasmid, or B16 frozen cells.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Interleukin-12 / genetics. Melanoma, Experimental / therapy. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395592.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 187348-17-0 / Interleukin-12
  •  go-up   go-down


15. García-Barros M, Thin TH, Maj J, Cordon-Cardo C, Haimovitz-Friedman A, Fuks Z, Kolesnick R: Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res; 2010 Oct 15;70(20):8179-86
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that the endothelium in MCA/129 fibrosarcomas and B16 melanomas exhibits a wild-type apoptotic phenotype in SCID hosts, abrogated in tumors in SCID(asmase-/-) littermates, which also acquire resistance to SDRT.
  • [MeSH-minor] Animals. Apoptosis / radiation effects. Cell Division / radiation effects. Crosses, Genetic. Fibrosarcoma / pathology. In Situ Nick-End Labeling. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL. Mice, SCID. Mutation. Severe Combined Immunodeficiency / genetics. Severe Combined Immunodeficiency / pathology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):425-37 [18500244.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4016-21 [17483312.001]
  • [Cites] Cancer Res. 2010 Feb 1;70(3):957-67 [20086180.001]
  • [Cites] J Clin Invest. 2010 Mar;120(3):694-705 [20179352.001]
  • [Cites] Semin Cancer Biol. 2010 Apr;20(2):116-24 [20219680.001]
  • [Cites] PLoS One. 2010;5(8):e12310 [20808818.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 22;284(4):1016-30 [11409897.001]
  • [Cites] Radiat Res. 2002 Sep;158(3):251-91 [12175305.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Oncogene. 2003 Oct 13;22(45):7070-7 [14557812.001]
  • [Cites] Science. 2003 Dec 12;302(5652):1894; author reply 1894 [14671275.001]
  • [Cites] Science. 2003 Dec 12;302(5652):1894; author reply 1894 [14671277.001]
  • [Cites] Cancer Cell. 2004 May;5(5):429-41 [15144951.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):101-8 [7061244.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1120-3 [3943089.001]
  • [Cites] Nature. 1990 Oct 4;347(6292):479-82 [2215662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1394-7 [1996340.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1244-8 [8443804.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):988-93 [8496984.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):57-66 [8175446.001]
  • [Cites] J Exp Med. 1994 Aug 1;180(2):525-35 [8046331.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2249-52 [7757972.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3344-9 [8764132.001]
  • [Cites] J Biol Chem. 1998 Feb 13;273(7):4081-8 [9461601.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4987-92 [15958537.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):89-91 [16098459.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8352-5 [16951142.001]
  • [Cites] Magn Reson Med. 2007 May;57(5):950-9 [17457861.001]
  • [Cites] Eur Radiol. 2009 Nov;19(11):2663-71 [19504109.001]
  • (PMID = 20924105.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085704; United States / NCI NIH HHS / CA / R01 CA085704; United States / NCI NIH HHS / CA / R01 CA105125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS231831; NLM/ PMC2976483
  •  go-up   go-down


16. Fernandes NV, Guntipalli PK, Mo H: d-δ-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells. Anticancer Res; 2010 Dec;30(12):4937-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] d-δ-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells.
  • BACKGROUND: The rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides essential intermediates for the prenylation or dolichylation of growth-related proteins. d-δ-tocotrienol, a post-transcriptional down-regulator of HMG CoA reductase, suppresses the proliferation of murine B16 melanoma cells.
  • Dietary d-δ-tocotrienol suppresses the growth of implanted B16 melanomas without toxicity to host mice.
  • MATERIALS AND METHODS: The proliferation of human A2058 and A375 melanoma cells following a 72 h incubation in 96-well plates was measured by CellTiter 96® Aqueous One Solution.
  • CONCLUSION: d-δ-Tocotrienol may have potential application in melanoma chemoprevention and/or therapy.
  • [MeSH-major] Apoptosis / drug effects. Cell Cycle / drug effects. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Vitamin E / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Vitamin E.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187473.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 1406-18-4 / Vitamin E; 1SRB74OWSI / tocotrienol, delta; 9LHU78OQFD / Lovastatin
  •  go-up   go-down


17. Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA: T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother; 2008 Jan;31(1):1-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell receptor gene therapy of established tumors in a murine melanoma model.
  • Adoptive cell transfer therapy using tumor-infiltrating lymphocytes for patients with metastatic melanoma has demonstrated significant objective response rates.
  • A retroviral vector was constructed encoding the pmel-1 TCR genes targeting the B16 melanoma antigen, gp100.
  • Upon transfer into B16 tumor-bearing mice, the genetically engineered lymphocytes significantly slowed tumor development.
  • When C57BL/6 lymphocytes were added to antigen-reactive pmel-1 T cells, a reduction in the ability of pmel-1 T cell to treat B16 melanomas was seen, suggesting that untransduced cells may be deleterious to TCR gene therapy.
  • [MeSH-major] Genetic Therapy / methods. Immunotherapy, Adoptive / methods. Melanoma, Experimental / therapy. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Animals. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / transplantation. Cell Line, Tumor. Coculture Techniques. Genetic Vectors / genetics. Immunophenotyping. Interferon-gamma / metabolism. Lymphocyte Activation / immunology. Lymphocytes / immunology. Lymphocytes / metabolism. Membrane Glycoproteins / genetics. Membrane Glycoproteins / immunology. Mice. Mice, Inbred C57BL. Mice, Transgenic. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / immunology. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Spleen / cytology. Spleen / immunology. Transfection. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2003 Aug 18;198(4):569-80 [12925674.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):3287-95 [12960359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 [14762166.001]
  • [Cites] Hum Gene Ther. 2004 Jul;15(7):648-58 [15242525.001]
  • [Cites] Exp Hematol. 1996 Feb;24(2):324-9 [8641361.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7209-16 [15585842.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):139-48 [15630141.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):349-54 [15723046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4518-23 [15758071.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4415-23 [15778407.001]
  • [Cites] Hum Gene Ther. 2005 Apr;16(4):457-72 [15871677.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] Clin Immunol. 2006 May;119(2):135-45 [16458072.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):383-93 [16622476.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8878-86 [16951205.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] Eur J Immunol. 2006 Nov;36(11):3052-9 [17051621.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):492-501 [17273561.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2331-8 [17082316.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2425-9 [17363559.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3898-903 [17440104.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3564-72 [17660381.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Nat Rev Immunol. 2002 Jul;2(7):512-9 [12094225.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):1105-13 [11034600.001]
  • [Cites] Blood. 2003 Jul 15;102(2):497-505 [12649146.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Protein Sci. 2006 Apr;15(4):710-21 [16600963.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • (PMID = 18157006.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010763-01; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Si protein, mouse; 0 / gp100 Melanoma Antigen; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS38363; NLM/ PMC2235937
  •  go-up   go-down


18. Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M: Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother; 2007 Sep;56(9):1417-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We treated mice bearing established subcutaneous B16 melanomas or RenCa renal cell carcinomas with intraperitoneal (i.p.) or subcutaneous (s.c.
  • Whereas both routes of IL-21 administration significantly inhibited growth of small, established RenCa and B16 tumors, only s.c. therapy significantly inhibited the growth of large, established tumors.
  • In accordance, both routes of IL-21 administration significantly increased the density of tumor infiltrating CD8(+) T cells in both B16 and RenCa tumors; and in the RenCa model s.c. administration of IL-21 led to a significantly higher density of tumor infiltrating CD8(+) T cells compared to i.p. administration.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Carcinoma, Renal Cell / therapy. Interleukins / therapeutic use. Kidney Neoplasms / therapy. Lymphocytes, Tumor-Infiltrating / immunology. Melanoma, Experimental / therapy. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285290.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukins; 0 / interleukin-21
  •  go-up   go-down


19. Søndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ: Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity. J Immunol; 2009 Dec 1;183(11):7326-36
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found intact immune surveillance toward methylcholanthrene-induced sarcomas in IL-21(-/-) and IL-21R(-/-) mice compared with wild-type mice and B16 melanomas showed equal growth kinetics and development of lung metastases.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19915059.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukins; 0 / Receptors, Interleukin-21; 0 / interleukin-21
  •  go-up   go-down


20. Fu P, Chen J, Tian Y, Watkins T, Cui X, Zhao B: Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor. Cancer Gene Ther; 2005 Mar;12(3):268-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After administration of hematopoietic cells carrying the ri gene, mice were implanted with B16 melanomas for 21 days.
  • [MeSH-major] Angiogenesis Inhibitors / genetics. Gene Expression Regulation. Genetic Therapy / methods. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / metabolism. Melanoma / therapy. Placental Hormones / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592448.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / DNA Primers; 0 / DNA, Complementary; 0 / Placental Hormones; 120178-77-0 / placental ribonuclease inhibitor; EC 3.1.27.- / angiogenin; EC 3.1.27.5 / Ribonuclease, Pancreatic
  •  go-up   go-down


21. Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG: Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther; 2010 Apr;21(4):439-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of oncolytic virotherapy using VSV against B16 melanomas in C57BL/6 mice is dependent on CD8(+) T and natural killer cells.
  • Because immunotherapies that prime specific CD8(+) T cells against melanocyte/melanoma antigens can generate significant therapeutic responses, we hypothesized that engineering VSV to express the potent T cell costimulatory molecule CD40 ligand (VSV-CD40L) would enhance virotherapy with concomitant priming of melanoma-specific T cells.
  • These observations suggest that an efficiently primed antitumor T cell response can produce similar, if not better, therapy against an established melanoma compared with intratumoral injection of a replication-competent oncolytic virus.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):425-30 [17354238.001]
  • [Cites] J Leukoc Biol. 2000 Jan;67(1):2-17 [10647992.001]
  • [Cites] Gene Ther. 2000 Sep;7(17):1467-76 [11001366.001]
  • [Cites] J Virol. 2000 Oct;74(20):9580-5 [11000229.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6391-5 [11103803.001]
  • [Cites] J Virol. 2001 Apr;75(7):3474-9 [11238874.001]
  • [Cites] Hepatology. 2001 Jul;34(1):72-81 [11431736.001]
  • [Cites] J Virol. 2002 Jan;76(2):895-904 [11752178.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5495-504 [12359759.001]
  • [Cites] J Virol. 2003 Aug;77(16):8843-56 [12885903.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):7-11 [12892708.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5505-12 [14500387.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8366-76 [14678998.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):51-65 [14749126.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):210-6 [15121047.001]
  • [Cites] Nat Biotechnol. 2004 Sep;22(9):1125-32 [15300260.001]
  • [Cites] J Exp Med. 1992 Dec 1;176(6):1693-702 [1460426.001]
  • [Cites] Annu Rev Immunol. 1994;12:881-922 [7516669.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81 [7753828.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2569-74 [9205055.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2094-8 [9725199.001]
  • [Cites] Hum Gene Ther. 1999 May 20;10(8):1375-87 [10365667.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):350-8 [15565179.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7710-9 [16299531.001]
  • [Cites] Nat Med. 2008 Jan;14(1):37-44 [18066076.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4915-24 [18676766.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):1910-8 [18827807.001]
  • [Cites] Gene Ther. 2010 Feb;17(2):158-70 [20016540.001]
  • [Cites] Cancer Res. 2010 Jun 1;70(11):4539-49 [20484025.001]
  • [Cites] Mol Ther. 2006 Jan;13(1):221-8 [16257582.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):4168-77 [16951382.001]
  • [Cites] Gene Ther. 2006 Oct;13(20):1457-70 [16724095.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):300-8 [17210711.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2840-8 [17363607.001]
  • (PMID = 19922169.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107082; United States / NCI NIH HHS / CA / CA107082-02; United States / NCI NIH HHS / CA / R01 CA132734; United States / NCI NIH HHS / CA / CA132736; United States / NCI NIH HHS / CA / CA130878-01; United States / NCI NIH HHS / CA / R01 CA130878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 147205-72-9 / CD40 Ligand
  • [Other-IDs] NLM/ PMC2865217
  •  go-up   go-down


22. Sabel MS, Arora A, Su G, Griffith KA, Mathiowitz E, Reineke JJ, Chang AE: Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres. J Immunother; 2007 Nov-Dec;30(8):808-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C57BL6 mice with established B16 melanomas underwent a single intratumoral injection of IL-12, tumor necrosis factor-alpha, or IL-18 PLAM, alone or in combination.
  • [MeSH-major] Interleukin-12 / therapeutic use. Interleukin-18 / therapeutic use. Lactic Acid / chemistry. Melanoma, Experimental / drug therapy. Nanocapsules / chemistry. Polymers / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049332.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102602-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-18; 0 / Nanocapsules; 0 / Polymers; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12; 26100-51-6 / poly(lactic acid); 33X04XA5AT / Lactic Acid; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


23. Gangjee A, Zeng Y, Ihnat M, Warnke LA, Green DW, Kisliuk RL, Lin FT: Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg Med Chem; 2005 Sep 15;13(18):5475-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 18 and 32 were also evaluated in a B16 melanoma mouse model and were found to be more active as antitumor agents than methotrexate.
  • In addition, both 18 and 32 were also active in decreasing lung metastases in a mouse model of B16 melanomas.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039863.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA09885; United States / NCI NIH HHS / CA / CA10914
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Folic Acid Antagonists; 0 / Pyrimidines; EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Prins RM, Bruhn KW, Craft N, Lin JW, Kim CH, Odesa SK, Miller JF, Liau LM: Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden. Neurosurgery; 2006 Jan;58(1):169-78; discussion 169-78
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Previously, we demonstrated that a recombinant Listeria monocytogenes (rLM) vector encoding the melanoma-associated antigen, tyrosinase related protein (TRP)-2, could successfully treat subcutaneous B16 melanomas.
  • 1) to test whether this rLM-nucleoprotein (NP)/TRP-2 could generate antitumor immunity to a B16 tumor challenge in the immunologically privileged central nervous system (CNS) and 2) to develop a noninvasive imaging modality to monitor tumor progression in the brain after immunotherapy.
  • To noninvasively measure tumor growth within the CNS in vivo, we developed a B16 cell line expressing firefly luciferase that could be readily detected via bioluminescent imaging.
  • RESULTS: Vaccination with rLM-NP/TRP-2 induced a robust, tumor-specific CD8 T-cell response to the dominant cytotoxic T lymphocyte epitope of TRP-2 and selective interferon-gamma secretion when cocultured with B16 melanoma cells in vitro.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16385341.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-84008; United States / NIGMS NIH HHS / GM / GM07104; United States / NCI NIH HHS / CA / T32 CA09120-28; United States / PHS HHS / / 5-T32 A1007126-27; United States / NCI NIH HHS / CA / R01 CA127565; United States / NCI NIH HHS / CA / R25 CA 098010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Vaccines; 0 / Cancer Vaccines; 0 / Epitopes; 0 / Vaccines, Synthetic; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


25. Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E, Varea MT, Asensio G, Jordá L, Estrela JM: Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia; 2005 Jan;7(1):37-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma.
  • In vitro growth of highly malignant B16 melanoma F10 cells (B16M-F10) is inhibited (56%) by short-time exposure (60 min/day) to PTER (40 microm) and QUER (20 microm) (approximate mean values of plasma concentrations measured within the first hour after intravenous administration of 20 mg/kg each polyphenol).
  • Our findings demonstrate that the association of PTER and QUER inhibits metastatic melanoma growth and extends host survival.
  • [MeSH-major] Liver Neoplasms / drug therapy. Melanoma, Experimental / drug therapy. Phenols / therapeutic use. Quercetin / therapeutic use. Stilbenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] Free Radic Biol Med. 1997;22(7):1203-9 [9098094.001]
  • [Cites] J Cell Physiol. 1998 Mar;174(3):322-30 [9462694.001]
  • [Cites] FEBS Lett. 1998 Jan 16;421(3):277-9 [9468322.001]
  • [Cites] J Nat Prod. 1998 Mar;61(3):362-6 [9544566.001]
  • [Cites] Hepatology. 1998 May;27(5):1249-56 [9581678.001]
  • [Cites] Clin Chem. 1998 Jul;44(7):1423-9 [9665419.001]
  • [Cites] Blood. 1998 Aug 1;92(3):996-1002 [9680369.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21875-82 [9705326.001]
  • [Cites] Nutr Rev. 1998 Nov;56(11):317-33 [9838798.001]
  • [Cites] Life Sci. 1999;64(21):1869-76 [10353585.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2596-601 [10363980.001]
  • [Cites] Biochemistry. 1999 Oct 5;38(40):13244-51 [10529197.001]
  • [Cites] Life Sci. 2000 Jan 14;66(8):663-73 [10680575.001]
  • [Cites] J Pathol. 2000 Feb;190(3):310-29 [10685065.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):567-74 [10845555.001]
  • [Cites] Altern Med Rev. 2000 Jun;5(3):196-208 [10869101.001]
  • [Cites] Carcinogenesis. 2000 Aug;21(8):1619-22 [10910967.001]
  • [Cites] Free Radic Biol Med. 2000 Dec 15;29(12):1234-43 [11118813.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1604-10 [11245472.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1205-15 [11322924.001]
  • [Cites] Annu Rev Nutr. 2001;21:381-406 [11375442.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22586-94 [11316812.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1613-5 [11427503.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25775-82 [11313348.001]
  • [Cites] Clin Exp Metastasis. 2000;18(5):415-21 [11467774.001]
  • [Cites] Adv Exp Med Biol. 2001;492:159-82 [11480664.001]
  • [Cites] Cancer Lett. 2001 Sep 28;171(1):11-6 [11485823.001]
  • [Cites] Cell Physiol Biochem. 2001;11(4):173-86 [11509825.001]
  • [Cites] Free Radic Biol Med. 2001 Sep 1;31(5):642-50 [11522449.001]
  • [Cites] J Agric Food Chem. 2002 Jun 5;50(12):3453-7 [12033810.001]
  • [Cites] Annu Rev Nutr. 2002;22:19-34 [12055336.001]
  • [Cites] Free Radic Biol Med. 2002 Aug 1;33(3):387-98 [12126761.001]
  • [Cites] Clin Biochem. 2003 Feb;36(1):79-87 [12554065.001]
  • [Cites] BMC Cancer. 2002 Oct 17;2:27 [12383351.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13888-97 [12578841.001]
  • [Cites] J Cell Biochem. 2003 Aug 1;89(5):1044-55 [12874837.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39591-9 [12881529.001]
  • [Cites] FASEB J. 2003 Nov;17(14):1975-85 [14597667.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2339-41 [14563682.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):829-37 [15019968.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):838-49 [15019969.001]
  • [Cites] J Theor Biol. 1985 Jun 7;114(3):413-31 [4021503.001]
  • [Cites] J Natl Cancer Inst. 1986 Jun;76(6):1247-54 [3486997.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Jpn J Cancer Res. 1989 Sep;80(9):818-21 [2513297.001]
  • [Cites] Anal Chem. 1989 Dec 15;61(24):2715-8 [2619057.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6676-81 [1423313.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3233-6 [7515767.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):414-9 [7529137.001]
  • [Cites] Biochem Soc Symp. 1995;61:1-31 [8660387.001]
  • [Cites] Ann Intern Med. 1996 Sep 1;125(5):384-9 [8702089.001]
  • (PMID = 15736313.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alpha4beta1; 0 / Nitrates; 0 / Nitrites; 0 / Phenols; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Stilbenes; 0 / Vascular Cell Adhesion Molecule-1; 537-42-8 / pterostilbene; 9IKM0I5T1E / Quercetin; BBX060AN9V / Hydrogen Peroxide
  • [Other-IDs] NLM/ PMC1490314
  •  go-up   go-down


26. Janczak M, Kapuściński J, Olasik EM, Rózalski M, Płachcińska A, Kuśmierek J: Biodistribution of two (131)I-IMBA preparations, differently labelled, in mice with experimental B16 melanoma tumours. Nucl Med Rev Cent East Eur; 2008;11(2):48-52
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biodistribution of two (131)I-IMBA preparations, differently labelled, in mice with experimental B16 melanoma tumours.
  • BACKGROUND: Numerous reports indicate that some iodinated compounds of benzamide derivatives display a strong affinity to the cells of melanoma.
  • Biodistribution of the injected compound was followed in mice with experimentally induced B16 melanoma tumours, and tumour/ tissue ratios were studied as a function of time post administration.
  • The biodistribution of (131)I-IMBA in C57 Black mice was studied in animals with experimentally induced B16 mice melanoma tumours.
  • RESULTS: The mean labelling efficiency exceeded 95 and 80 % for methods I and II, respectively, at radiochemical purity > 95% in both cases. (131)I-IMBA was vividly cumulated by melanoma tumours in mice.
  • CONCLUSIONS: High values of tumour/non-tumour ratios indicate that (131)I-IMBA could be a promising radiopharmaceutical for clinical diagnosis (staging) of melanomas in humans.
  • [MeSH-major] Benzamides / pharmacokinetics. Iodobenzenes / pharmacokinetics. Melanoma / metabolism. Melanoma / radionuclide imaging. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585454.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Benzamides; 0 / Iodobenzenes; 0 / N-(2-diethylaminoethyl)-3-iodo-4-methoxybenzamide; 0 / Radiopharmaceuticals
  •  go-up   go-down


27. Miyano-Kurosaki N, Kurosaki K, Hayashi M, Takaku H, Hayafune M, Shirato K, Kasuga T, Endo T, Tomoda A: 2-aminophenoxazine-3-one suppresses the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice. Biol Pharm Bull; 2006 Nov;29(11):2197-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-aminophenoxazine-3-one suppresses the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice.
  • Since phenoxazine is an essential structure of actinomycin D, which exerts a strong anticancer effect, we examined the anticancer effect of 2-aminophenoxazine-3-one (Phx-3) on mouse malignant melanoma B16 cells in vitro and in vivo.
  • Phx-3 inhibited proliferation of the B16 cells in a dose-dependent manner in vitro.
  • We furthermore studied the in vivo effects of Phx-3 on mouse malignant melanoma B16 cells transplanted in female C57BL/6Cr Slc mice.
  • Treatment with Phx-3 (0.5 mg/kg) completely suppressed the growth of mouse malignant melanoma B16 cells transplanted in mice as compared with the control group.
  • These results suggest that Phx-3 may be used to treat patients affected by malignant melanoma in future.
  • [MeSH-major] Cell Proliferation / drug effects. Melanoma, Experimental / prevention & control. Oxazines / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17077514.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Oxazines; 1916-59-2 / 3-aminophenoxazone; AYI8EX34EU / Creatinine; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


28. Ferrer P, Asensi M, Priego S, Benlloch M, Mena S, Ortega A, Obrador E, Esteve JM, Estrela JM: Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma. J Biol Chem; 2007 Feb 2;282(5):2880-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma.
  • Intravenous administration to mice of trans-pterostilbene (t-PTER; 3,5-dimethoxy-4'-hydroxystilbene) and quercetin (QUER; 3,3',4',5,6-pentahydroxyflavone), two structurally related and naturally occurring small polyphenols, inhibits metastatic growth of highly malignant B16 melanoma F10 (B16M-F10) cells. t-PTER and QUER inhibit bcl-2 expression in metastatic cells, which sensitizes them to vascular endothelium-induced cytotoxicity.
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Line, Tumor. Endothelium, Vascular / physiology. Endothelium, Vascular / physiopathology. Hydrogen Peroxide / metabolism. Male. Melanoma. Mice. Mice, Inbred C57BL. Mitochondrial Membranes / physiology. Neoplasm Metastasis. Nitrates / metabolism. Nitrites / metabolism. Polyphenols. Proto-Oncogene Proteins c-bcl-2 / genetics. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135264.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Nitrates; 0 / Nitrites; 0 / Phenols; 0 / Polyphenols; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 31C4KY9ESH / Nitric Oxide; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


29. Sun B, Zhang S, Zhang D, Yin X, Wang S, Gu Y, Wang Y: Doxycycline influences microcirculation patterns in B16 melanoma. Exp Biol Med (Maywood); 2007 Nov;232(10):1300-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxycycline influences microcirculation patterns in B16 melanoma.
  • To examine the effects of doxycycline on invasion-related protein expression and proliferation of melanoma cells and to evaluate its effect on microcirculation patterns in melanoma, we injected murine melanoma B16 cell suspensions into the groin areas of C57BL/6 mice that were randomly divided into treatment and control groups.
  • Doxycycline treatment partly suppressed the growth of engrafted B16 melanoma, with an inhibition rate of 35.63%.
  • Doxycycline inhibits the growth of engrafted melanoma and results in reduced expression of MMP-2, MMP-9, and VM formations.
  • [MeSH-major] Doxycycline / pharmacology. Melanoma, Experimental / blood supply. Microcirculation / drug effects

  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17959842.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases; N12000U13O / Doxycycline
  •  go-up   go-down


30. Mazorra Z, Mesa C, Fernández A, Fernández LE: Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge. Cancer Immunol Immunother; 2008 Dec;57(12):1771-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
  • The overexpression of GM3 ganglioside in murine and human melanomas and its important role in tumour progression makes this self antigen a potential target for preventive immunotherapy of this neoplasm.
  • We have previously shown that preventive administration of a GM3-based vaccine to C57BL/6 mice elicited the rejection of the GM3 positive-B16 melanoma cells in most of the animals.
  • In addition, T cells from surviving-immunized animals secreted IFNgamma when were co-cultured with IFNalpha-treated B16 melanoma cells or DCs pulsed with melanoma extract.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Cancer Vaccines / immunology. G(M3) Ganglioside / immunology. Melanoma, Experimental / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351335.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Cancer Vaccines; 0 / G(M3) Ganglioside; 0 / Immunoglobulin G; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


31. Lee YS, Kim DW, Kim S, Choi HI, Lee Y, Kim CD, Lee JH, Lee SD, Lee YH: Downregulation of NFAT2 promotes melanogenesis in B16 melanoma cells. Anat Cell Biol; 2010 Dec;43(4):303-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of NFAT2 promotes melanogenesis in B16 melanoma cells.
  • Western blot analysis was performed to investigate the expression of NFAT2 protein in B16 melanoma cells.
  • Our data showed that NFAT2 expression was increased in the hypopigmented B16 cells, while tyrosinase and MITF expression was decreased.
  • To investigate the potential role of NFAT2, the recombinant adenovirus expressing microRNA specific for NFAT2 was transduced into the cultured B16 melanoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9575-80 [11493684.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2476-89 [11402342.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [Cites] FASEB J. 2007 Apr;21(4):976-94 [17242160.001]
  • [Cites] Dev Genes Evol. 2008 Jan;218(1):23-32 [18175145.001]
  • [Cites] Cell. 2008 Jan 25;132(2):299-310 [18243104.001]
  • [Cites] Mol Biol Rep. 2009 Jul;36(6):1247-50 [18600473.001]
  • [Cites] FASEB J. 2008 Dec;22(12):4218-27 [18708588.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1448-55 [19724275.001]
  • [Cites] Immunol Rev. 2009 Sep;231(1):160-73 [19754896.001]
  • [Cites] Immunol Rev. 2009 Sep;231(1):210-24 [19754899.001]
  • [Cites] Am J Transl Res. 2009;1(2):184-202 [19956430.001]
  • [Cites] Nature. 2010 May 20;465(7296):368-72 [20485437.001]
  • [Cites] Blood. 2010 Sep 16;116(11):e18-25 [20511541.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):205-11 [8175909.001]
  • [Cites] J Dermatol Sci. 1997 Mar;14(3):199-206 [9138477.001]
  • [Cites] Front Biosci. 2006;11:2157-73 [16720302.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2218-26 [17522069.001]
  • [Cites] J Mol Cell Cardiol. 2009 Sep;47(3):400-10 [19540841.001]
  • [Cites] J Cell Physiol. 1990 Feb;142(2):334-41 [2303529.001]
  • [Cites] Lab Invest. 1987 Jun;56(6):684-6 [3599911.001]
  • [Cites] Transplantation. 1995 Aug 27;60(4):362-8 [7652766.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28052-6 [8910416.001]
  • [Cites] Nature. 1997 Jan 9;385(6612):172-6 [8990122.001]
  • [Cites] Annu Rev Immunol. 1999;17:149-87 [10358756.001]
  • [Cites] Pigment Cell Res. 2000;13 Suppl 8:98-102 [11041365.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jun;284(6):C1593-603 [12734112.001]
  • (PMID = 21267404.001).
  • [ISSN] 2093-3673
  • [Journal-full-title] Anatomy & cell biology
  • [ISO-abbreviation] Anat Cell Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026182
  • [Keywords] NOTNLM ; B16 melanoma cells / Cyclosprorin A / Melanocyte / Melanogenesis / NFAT2
  •  go-up   go-down


32. Murozuka Y, Kasuya MC, Kobayashi M, Watanabe Y, Sato T, Hatanaka K: Efficient sialylation on azidododecyl lactosides by using B16 melanoma cells. Chem Biodivers; 2005 Aug;2(8):1063-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient sialylation on azidododecyl lactosides by using B16 melanoma cells.
  • To establish the optimal condition for the bioproduction of a large amount of valuable materials containing GM3-type oligosaccharides, two kinds of lactoside primers having the azido group in different positions were synthesized and introduced into B16 melanoma cells.
  • These results represent the optimal conditions that are necessary for the mass production of GM3-type oligosaccharide using azidododecyl lactoside primers and B16 cells.
  • [MeSH-major] Glycosphingolipids / chemistry. Glycosphingolipids / metabolism. Melanoma, Experimental / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17193190.001).
  • [ISSN] 1612-1880
  • [Journal-full-title] Chemistry & biodiversity
  • [ISO-abbreviation] Chem. Biodivers.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Glycosphingolipids
  •  go-up   go-down


33. Gatouillat G, Balasse E, Joseph-Pietras D, Morjani H, Madoulet C: Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem; 2010 Jul 1;110(4):893-902
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma.
  • In this study, we show that resveratrol (0-500 microM) inhibits the growth of a doxorubicin-resistant B16 melanoma cell subline (B16/DOX) (IC(50) = 25 microM after 72 h, P < 0.05).
  • The G(1)-phase arrest of cell cycle in resveratrol-treated (10-100 microM) B16/DOX cells was followed by the induction of apoptosis, which was revealed by pyknotic nuclei and fragmented DNA.
  • Resveratrol also potentiated at subtoxic dose (25 microM for 24 h) doxorubicin cytotoxicity in the chemoresistant B16 melanoma (P < 0.01).
  • When administered to mice, resveratrol (12.5 mg/kg) reduced the growth of an established B16/DOX melanoma and prolonged survival (32% compared to untreated mice).
  • [MeSH-major] Apoptosis / drug effects. Cell Cycle / drug effects. Melanoma, Experimental / pathology. Stilbenes / pharmacology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Cell. Biochem. 110: 893-902, 2010. (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20564188.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Stilbenes; 80168379AG / Doxorubicin; Q369O8926L / resveratrol
  •  go-up   go-down


34. Matsuda H, Nakashima S, Oda Y, Nakamura S, Yoshikawa M: Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells. Bioorg Med Chem; 2009 Aug 15;17(16):6048-53
BindingDB. BindingDB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
  • The 80% aqueous acetone extract from the rhizomes of Alpinia officinarum, a Chinese medicinal herb, were found to inhibit melanogenesis in theophylline-stimulated murine B16 melanoma 4A5 cells.
  • [MeSH-major] Alpinia / chemistry. Antineoplastic Agents / chemistry. Enzyme Inhibitors / chemistry. Melanoma, Experimental / drug therapy. Monophenol Monooxygenase / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615910.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Kaempferols; 0 / kaempferide; 142FWE6ECS / galangin; EC 1.- / Oxidoreductases; EC 1.14.18.- / tyrosinase-related protein-1; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


35. Koo JH, Kim HT, Yoon HY, Kwon KB, Choi IW, Jung SH, Kim HU, Park BH, Park JW: Effect of xanthohumol on melanogenesis in B16 melanoma cells. Exp Mol Med; 2008 Jun 30;40(3):313-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of xanthohumol on melanogenesis in B16 melanoma cells.
  • Xanthohumol (XH), the principal prenylflavonoid of the hop plant (Humulus lupulus L.), dose-dependently inhibited isobutylmethylxanthine (IBMX)-induced melanogenesis in B16 melanoma cells, with little cytotoxicity at the effective concentrations.
  • [MeSH-minor] 1-Methyl-3-isobutylxanthine / pharmacology. Animals. Cell Line. Cell Survival / drug effects. Colforsin / pharmacology. Dose-Response Relationship, Drug. Down-Regulation. Drug Antagonism. Flavonoids. Intramolecular Oxidoreductases / antagonists & inhibitors. Intramolecular Oxidoreductases / biosynthesis. Melanoma, Experimental. Membrane Glycoproteins / antagonists & inhibitors. Membrane Glycoproteins / biosynthesis. Mice. Microphthalmia-Associated Transcription Factor / antagonists & inhibitors. Microphthalmia-Associated Transcription Factor / biosynthesis. Monophenol Monooxygenase / antagonists & inhibitors. Monophenol Monooxygenase / biosynthesis. Monophenol Monooxygenase / genetics. Oxidoreductases / antagonists & inhibitors. Oxidoreductases / biosynthesis. Signal Transduction / drug effects. alpha-MSH / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):24-8 [10537003.001]
  • [Cites] Mol Pharmacol. 1970 Nov;6(6):597-603 [4322367.001]
  • [Cites] Pigment Cell Res. 2000 Apr;13(2):60-9 [10841026.001]
  • [Cites] Pigment Cell Res. 2000 Aug;13(4):230-40 [10952390.001]
  • [Cites] Pigment Cell Res. 2000 Aug;13(4):248-52 [10952392.001]
  • [Cites] J Agric Food Chem. 2000 Sep;48(9):3876-84 [10995285.001]
  • [Cites] Pigment Cell Res. 2000;13 Suppl 8:94-7 [11041364.001]
  • [Cites] Exp Mol Med. 2001 Sep 30;33(3):131-5 [11642548.001]
  • [Cites] Mol Cancer Ther. 2002 Sep;1(11):959-69 [12481418.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 7;301(2):610-6 [12565907.001]
  • [Cites] Phytochemistry. 2004 May;65(10):1317-30 [15231405.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] FEBS Lett. 1985 Apr 22;183(2):430-2 [2985438.001]
  • [Cites] Biosci Biotechnol Biochem. 1997 Jan;61(1):158-9 [9028043.001]
  • [Cites] Pigment Cell Res. 1997 Oct;10(5):288-97 [9359624.001]
  • [Cites] Antiviral Res. 2004 Dec;64(3):189-94 [15550272.001]
  • [Cites] In Vivo. 2005 Jan-Feb;19(1):103-7 [15796161.001]
  • [Cites] J Antimicrob Chemother. 2005 Jun;55(6):883-7 [15824094.001]
  • [Cites] Mol Nutr Food Res. 2005 Sep;49(9):837-43 [15995977.001]
  • [Cites] Mol Nutr Food Res. 2005 Sep;49(9):861-7 [16092070.001]
  • [Cites] Pigment Cell Res. 2006 Apr;19(2):146-53 [16524430.001]
  • [Cites] Trends Mol Med. 2006 Sep;12(9):406-14 [16899407.001]
  • [Cites] Acta Pharmacol Sin. 2006 Nov;27(11):1467-73 [17049123.001]
  • [Cites] Phytother Res. 2006 Nov;20(11):921-34 [16841367.001]
  • [Cites] Pigment Cell Res. 2006 Dec;19(6):550-71 [17083484.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]
  • [Cites] FASEB J. 2007 Apr;21(4):976-94 [17242160.001]
  • [Cites] Mutat Res. 2007 Aug 15;632(1-2):1-8 [17590382.001]
  • [Cites] Dermatol Clin. 2007 Jul;25(3):283-91, vii [17662894.001]
  • [Cites] J Biol Chem. 2007 Sep 21;282(38):27557-61 [17635904.001]
  • [Cites] Apoptosis. 2007 Nov;12(11):1953-63 [17874298.001]
  • [Cites] Int J Mol Med. 2007 Nov;20(5):763-7 [17912471.001]
  • [Cites] Methods Enzymol. 1987;142:165-9 [3037257.001]
  • [Cites] Int J Biochem. 1987;19(12):1141-7 [3125075.001]
  • [Cites] J Biol Chem. 1993 Jun 5;268(16):11742-9 [7685020.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):27080-7 [7929451.001]
  • [Cites] EMBO J. 1994 Dec 15;13(24):5818-25 [7813420.001]
  • [Cites] Recent Prog Horm Res. 1996;51:287-317; discussion 318 [8701084.001]
  • [Cites] Exp Cell Res. 2000 Mar 15;255(2):135-43 [10694430.001]
  • (PMID = 18587269.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Melanins; 0 / Membrane Glycoproteins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Mitf protein, mouse; 0 / Propiophenones; 1F7A44V6OU / Colforsin; 581-05-5 / alpha-MSH; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse; EC 1.14.18.1 / Monophenol Monooxygenase; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase; T4467YT1NT / xanthohumol; TBT296U68M / 1-Methyl-3-isobutylxanthine
  • [Other-IDs] NLM/ PMC2679287
  •  go-up   go-down


36. Wei J, Xiong Y: Inhibitory effect of recombinant fibronectin polypeptide CH50 on invasion and metastasis of melanoma B16 cells. J Huazhong Univ Sci Technolog Med Sci; 2007 Feb;27(1):17-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of recombinant fibronectin polypeptide CH50 on invasion and metastasis of melanoma B16 cells.
  • In order to investigate the inhibitory effect and mechanism of recombinant polypeptide CH50 on invasion and metastasis of melanoma B16 cells, the recombinant polypeptide CH50 was separated and purified by ion exchange chromatographic technique.
  • The melanoma B16 cells treated with purified CH50 were cultured in vitro, the number was counted at 4, 24, 48 and 72 h and their morphological changes were observed in order to detect their adhesion and spreading abilities.
  • In in vivo study, the melanoma B16 cells were labeled with CFSE and treated with CH50 and then they were injected into mice via mouse-tail veins.
  • Accumulation and invasion abilities of B16 cells on lung tissues were observed under the fluorescent microscopy.
  • The results showed that the morphological character of B16 cells treated with CH50 changed greatly and the number of B16 cells treated with CH50 decreased significantly (P<0.05).
  • The adhesion and spreading abilities of B16 cells treated with CH50 were weakened obviously and the metastasis foci on lung tissues reduced.
  • It was concluded that the recombinant polypeptide CH50 inhibited invasion and metastasis of melanoma B16 cells on tissues and could be a prospective bio-product in tumor general therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Fibronectins / pharmacology. Melanoma, Experimental / pathology. Neoplasm Invasiveness / prevention & control. Neoplasm Metastasis / prevention & control. Recombinant Proteins / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393099.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CH50 recombinant polypeptide; 0 / Fibronectins; 0 / Recombinant Proteins
  •  go-up   go-down


37. Sitdikova SM, Amandzholov BS, Kiselevskii MV, Donenko FV: Specificity of relapses and metastases of experimental transplanted Ehrlich carcinoma and B16 melanoma. Bull Exp Biol Med; 2007 Jan;143(1):80-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specificity of relapses and metastases of experimental transplanted Ehrlich carcinoma and B16 melanoma.
  • Experiments on female (CBAxC57Bl/6)F1 mice with simultaneously transplanted Ehrlich carcinoma and B16 melanoma showed that removal of one of the primary nodes led to metastasizing of the removed tumor alone.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / secondary. Melanoma, Experimental / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019019.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ohguchi K, Akao Y, Nozawa Y: Involvement of calpain in melanogenesis of mouse B16 melanoma cells. Mol Cell Biochem; 2005 Jul;275(1-2):103-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of calpain in melanogenesis of mouse B16 melanoma cells.
  • In the current study, the involvement of calpain, a cysteine proteinase in the regulation of melanogenesis was examined using mouse B16 melanoma cells.
  • In response to alpha-melanocyte-stimulating hormone (a-MSH), B16 melanoma cells underwent differentiation characterized by increased melanin biosynthesis.
  • Treatment of B16 cells with ALLN caused marked decrease in both tyrosinase protein and mRNA levels.
  • These results indicate that calpain would be involved in the melanogenic signaling by modulating the expression of tyrosinase in mouse B16 melanoma cells.
  • [MeSH-minor] Animals. Blotting, Western. Calcium-Binding Proteins / pharmacology. Cell Differentiation / drug effects. Cysteine Proteinase Inhibitors / pharmacology. Electrophoresis, Polyacrylamide Gel. Hormones / pharmacology. Indolequinones / analysis. Leupeptins / pharmacology. Melanins / biosynthesis. Melanoma, Experimental. Mice. Monophenol Monooxygenase / analysis. Monophenol Monooxygenase / metabolism. RNA, Messenger / metabolism. Tumor Cells, Cultured. alpha-MSH / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16335789.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Cysteine Proteinase Inhibitors; 0 / Hormones; 0 / Indolequinones; 0 / Leupeptins; 0 / Melanins; 0 / RNA, Messenger; 110044-82-1 / acetylleucyl-leucyl-norleucinal; 3571-34-4 / dopachrome; 581-05-5 / alpha-MSH; 79079-11-1 / calpastatin; EC 1.14.18.1 / Monophenol Monooxygenase; EC 3.4.22.- / Calpain
  •  go-up   go-down


39. Jeong YM, Li H, Kim SY, Yun HY, Baek KJ, Kwon NS, Kim DS: Imidazole inhibits B16 melanoma cell migration via degradation of beta-catenin. J Pharm Pharmacol; 2010 Apr;62(4):491-6
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imidazole inhibits B16 melanoma cell migration via degradation of beta-catenin.
  • OBJECTIVES: In the present study, we determined whether or not imidazole affects B16 murine melanoma cell migration to prevent melanoma metastasis.
  • METHODS: To determine the effects of imidazole on melanoma cell migration, B16 cells were treated with imidazole at various concentrations, and the migration was measured using a scratch migration assay.
  • KEY FINDINGS: Imidazole did not exhibit cytotoxic effects on B16 cells at a concentration below 100 microm.
  • Our results showed that imidazole significantly inhibits B16 cell migration.
  • It is known that the Wnt/beta-catenin signalling pathway regulates the progression of melanocytic tumours and determines the prognosis in cutaneous melanomas.
  • Moreover, inhibition of melanoma cell migration by imidazole was restored by MG132, a proteasome inhibitor, via inhibition of beta-catenin degradation.
  • CONCLUSIONS: Imidazole inhibits B16 cell migration through beta-catenin degradation, suggesting that imidazole is a potential candidate for the treatment of metastatic melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Movement / drug effects. Imidazoles / therapeutic use. Melanoma / drug therapy. Signal Transduction / drug effects. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20604839.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Imidazoles; 0 / Leupeptins; 0 / beta Catenin; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 7GBN705NH1 / imidazole
  •  go-up   go-down


40. Lee YS, Kim HK, Lee KJ, Jeon HW, Cui S, Lee YM, Moon BJ, Kim YH, Lee YS: Inhibitory effect of glyceollin isolated from soybean against melanogenesis in B16 melanoma cells. BMB Rep; 2010 Jul;43(7):461-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of glyceollin isolated from soybean against melanogenesis in B16 melanoma cells.
  • We found that glyceollin inhibits melanin synthesis and tyrosinase activity in B16 melanoma cells without cytotoxicity.
  • Additionally, glyceollin effectively inhibited intracellular cAMP levels in B16 melanoma cells stimulated by alpha-melanocyte stimulating hormone (alpha-MSH).
  • These results suggest that the whitening activity of glyceollin may be due to the inhibition of cAMP involved in the signal pathway of alpha-MSH in B16 melanoma cells.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cyclic AMP / metabolism. Intramolecular Oxidoreductases / antagonists & inhibitors. Intramolecular Oxidoreductases / metabolism. Melanoma, Experimental / enzymology. Melanoma, Experimental / metabolism. Monophenol Monooxygenase / antagonists & inhibitors. Monophenol Monooxygenase / metabolism. Oxidoreductases / antagonists & inhibitors. Oxidoreductases / metabolism. Signal Transduction. alpha-MSH / metabolism

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663406.001).
  • [ISSN] 1976-670X
  • [Journal-full-title] BMB reports
  • [ISO-abbreviation] BMB Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Melanins; 0 / Pterocarpans; 581-05-5 / alpha-MSH; 6461TV6UCH / glyceollin; E0399OZS9N / Cyclic AMP; EC 1.- / Oxidoreductases; EC 1.14.18.- / tyrosinase-related protein-1; EC 1.14.18.1 / Monophenol Monooxygenase; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


41. Ohguchi K, Koike M, Suwa Y, Koshimizu S, Mizutani Y, Nozawa Y, Akao Y: Inhibitory effects of whisky congeners on melanogenesis in mouse B16 melanoma cells. Biosci Biotechnol Biochem; 2008 Apr;72(4):1107-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of whisky congeners on melanogenesis in mouse B16 melanoma cells.
  • We examined the effect of whisky congeners, substances other than ethanol in whisky, on melanogenesis in mouse B16 melanoma cells.
  • [MeSH-major] Alcoholic Beverages. Flavonoids / pharmacology. Melanins / biosynthesis. Melanoma, Experimental / metabolism. Phenols / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391453.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Melanins; 0 / Phenols; 0 / Polyphenols; 581-05-5 / alpha-MSH; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


42. Ohguchi K, Akao Y, Nozawa Y: Stimulation of melanogenesis by the citrus flavonoid naringenin in mouse B16 melanoma cells. Biosci Biotechnol Biochem; 2006 Jun;70(6):1499-501
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of melanogenesis by the citrus flavonoid naringenin in mouse B16 melanoma cells.
  • In this study, we examined the effect of naringenin on melanogenesis in mouse B16 melanoma cells.
  • [MeSH-major] Citrus / chemistry. Flavanones / pharmacology. Melanins / metabolism. Melanoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794334.001).
  • [ISSN] 0916-8451
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Flavanones; 0 / Melanins; HN5425SBF2 / naringenin
  •  go-up   go-down


43. Yamaoka Y, Ohguchi K, Itoh T, Nozawa Y, Akao Y: Effects of theaflavins on melanin biosynthesis in mouse b16 melanoma cells. Biosci Biotechnol Biochem; 2009 Jun;73(6):1429-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of theaflavins on melanin biosynthesis in mouse b16 melanoma cells.
  • In this study, we examined the effects of theaflavins, polyphenols in black tea, on alpha melanocyte-stimulating hormone (alphaMSH)-induced melanogenesis in mouse B16 melanoma cells.
  • [MeSH-major] Biflavonoids / pharmacology. Catechin / pharmacology. Melanins / biosynthesis. Melanoma, Experimental / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502752.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biflavonoids; 0 / DNA Primers; 0 / Melanins; 0 / RNA, Messenger; 1IA46M0D13 / theaflavin; 8R1V1STN48 / Catechin; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


44. Ohguchi K, Ito M, Yokoyama K, Iinuma M, Itoh T, Nozawa Y, Akao Y: Effects of sesquiterpene lactones on melanogenesis in mouse B16 melanoma cells. Biol Pharm Bull; 2009 Feb;32(2):308-10
National BioResource Project. culture/stock collections - NBRP resources .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of sesquiterpene lactones on melanogenesis in mouse B16 melanoma cells.
  • In this study, we examined the effect of sesquiterpene lactones isolated from Calea urticifolia and Tanacetum parthenium (feverfew) on melanogenesis in mouse B16 melanoma cells.
  • In response to 3-isobutyl-1-methylxanthin (IBMX), B16 melanoma cells underwent differentiation characterized by increased melanin biosynthesis.
  • Treatment of B16 cells with 2,3-epoxyjuanislamin elicited significant decreases in tyrosinase protein and mRNA levels.
  • [MeSH-major] Lactones / pharmacology. Melanins / biosynthesis. Melanoma, Experimental / metabolism. Sesquiterpenes / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19182396.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Lactones; 0 / Melanins; 0 / Phosphodiesterase Inhibitors; 0 / Plant Extracts; 0 / Sesquiterpenes; EC 1.14.18.1 / Monophenol Monooxygenase; TBT296U68M / 1-Methyl-3-isobutylxanthine
  •  go-up   go-down


45. Koo JH, Lee I, Yun SK, Kim HU, Park BH, Park JW: Saponified sunflower and safflower oils inhibit melanogenesis in B16 melanoma cells. Mol Med Rep; 2010 Mar-Apr;3(2):281-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Saponified sunflower and safflower oils inhibit melanogenesis in B16 melanoma cells.
  • Saponified sunflower (sap-SU) and safflower (sap-SA) oils dose-dependently inhibited isobutylmethylxanthine-induced melanogenesis in B16 melanoma cells, with no cytotoxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21472234.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


46. Chang TS, Lin JJ: Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells. Arch Pharm Res; 2010 Dec;33(12):1959-65
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells.
  • In the present study, more than 200 generic drugs were screened to verify their applicability as a skin-lightening agent using mouse B16 melanoma cells.
  • Of the numerous agents, danazol was found to inhibit melanogenesis in B16 cells in a dose-dependent manner with an IC(50) value of 9.3 μM.
  • In addition, danazol reduced cellular tyrosinase activity in B16 cells but did not directly inhibit the murine tyrosinase activity in the cell-free system.
  • Western blotting analysis confirmed that danazol downregulated the levels of tyrosinase protein in B16 cells, and reverse-transcription polymerase chain reaction (RT-PCR) analysis revealed that danazol did not downregulate the levels of tyrosinase mRNA in the cells.
  • These results indicate that danazol inhibits melanogenesis in B16 cells via reducing the tyrosinase activity by post-transcriptional regulation.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell-Free System / metabolism. Dose-Response Relationship, Drug. Down-Regulation. Drug Evaluation, Preclinical. High-Throughput Screening Assays. Melanoma, Experimental. Mice. Monophenol Monooxygenase / genetics. Monophenol Monooxygenase / metabolism. RNA, Messenger / metabolism. Transcription, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21191761.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Melanins; 0 / RNA, Messenger; EC 1.14.18.1 / Monophenol Monooxygenase; N29QWW3BUO / Danazol
  •  go-up   go-down


47. Seo WG, Hwang JC, Kang SK, Jin UH, Suh SJ, Moon SK, Kim CH: Suppressive effect of Zedoariae rhizoma on pulmonary metastasis of B16 melanoma cells. J Ethnopharmacol; 2005 Oct 3;101(1-3):249-57
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressive effect of Zedoariae rhizoma on pulmonary metastasis of B16 melanoma cells.
  • The inhibitory effect of Curcuma zedoaria Roscoe (WE-CZ) on experimental pulmonary metastasis of B16 melanoma cells was investigated.
  • When the duration of WE-CZ intake was examined, survival time was not affected by pre-intake before B16 melanoma cell inoculation and was slightly extended by post-intake after B16 melanoma cell inoculation, although the life span was prolonged by intake throughout the experiment.
  • The elevated NO was found to serve as a cytotoxic mediator against B16 melanoma cells in co-culture with macrophages.
  • On the contrary, B16 melanoma-conditioned medium reduced NO production by macrophages.
  • These findings indicate that WE-CZ possesses anti-migratory effects on B16 melanoma cells and that the macrophage function-modulating activity by WE-CZ appears to underlie its anti-metastatic activity, which leads to a decrease in the number of lung metastatic surface nodules and the extension of life span.
  • [MeSH-major] Curcuma. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Melanoma, Experimental / drug therapy. Phytotherapy. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023317.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Plant Extracts; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


48. Triba MN, Starzec A, Bouchemal N, Guenin E, Perret GY, Le Moyec L: Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells. NMR Biomed; 2010 Nov;23(9):1009-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells.
  • The metabolomic profiles of B16 melanoma cells were investigated in vitro with high resolution-magic angle spinning proton magnetic resonance spectroscopy and OPLS multivariate statistical analyse.
  • We compared the profiles for untreated melanoma B16-F10 cells and Ca(2+) chelating EGTA, doxorubicin or BP7033 bisphosphonate treated cells.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Doxorubicin / therapeutic use. Magnetic Resonance Spectroscopy / methods. Melanoma, Experimental. Metabolomics / methods

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20963798.001).
  • [ISSN] 1099-1492
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 80168379AG / Doxorubicin
  •  go-up   go-down


49. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF: Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res; 2008 May 15;14(10):3156-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
  • EXPERIMENTAL DESIGN: B16 melanoma cells were engineered to express the model SIYRYYGL (SIY) antigen to enable immune monitoring.
  • To determine whether Treg depletion could synergize with homeostatic proliferation, RAG2-/- mice received total or CD25-depleted T cells, followed or preceded by B16.SIY challenge.
  • RESULTS: Adoptive transfer of total splenic T cells into RAG2-/- mice moderately affected the growth rate of B16.SIY.
  • Interestingly, transfer of CD25-depleted T cells into RAG2-/- mice resulted in potent rejection of B16 melanoma in both prophylactic and short-term preimplanted tumor settings and was associated with maintained T-cell effector function.
  • [MeSH-major] Cell Proliferation. Homeostasis / immunology. Immunotherapy, Adoptive / methods. Lymphocyte Depletion. Melanoma, Experimental / therapy. T-Lymphocytes, Regulatory / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483384.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA97296; United States / NCI NIH HHS / CA / R01 CA118153
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Huang X, Yamada Y, Kidoya H, Naito H, Nagahama Y, Kong L, Katoh SY, Li WL, Ueno M, Takakura N: EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis. Cancer Res; 2007 Oct 15;67(20):9800-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
  • Here we found that overexpression of EphB4 in B16 melanoma cells suppressed tumor growth in a s.c. transplantation tumor model.
  • Histologic examination of these tumors revealed that EphB4 overexpression in B16 cells selectively suppressed arterial ephrinB2+ EC development.
  • By coculturing ephrinB2-expressing SV40-transformed mouse ECs (SVEC) with EphB4-overexpressing B16 cells, we found that EphB4 induced the apoptosis of SVECs.
  • However, ephrinB2 did not induce the apoptosis of EphB4-overexpressing B16 cells.
  • Based on results from these experiments, we concluded that EphB4 overexpression in B16 tumor cells suppresses the survival of arterial ECs in tumors by a reverse signaling via ephrinB2.
  • [MeSH-major] Melanoma, Experimental / blood supply. Receptor, EphB4 / biosynthesis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942910.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Ephrin-B2; EC 2.7.1.- / Ephb4 protein, mouse; EC 2.7.10.1 / Receptor, EphB4
  •  go-up   go-down


51. Nakashima S, Matsuda H, Oda Y, Nakamura S, Xu F, Yoshikawa M: Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells. Bioorg Med Chem; 2010 Mar 15;18(6):2337-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells.
  • The methanolic extract from the whole plants of Anastatica hierochuntica, an Egyptian herbal medicine, was found to inhibit melanogenesis in theophylline-stimulated murine B16 melanoma 4A5 cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brassicaceae / chemistry. Enzyme Inhibitors / pharmacology. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Plant Extracts / pharmacology

  • BindingDB. BindingDB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [RepublishedFrom] Bioorg Med Chem. 2010 Jan 1;18(1):182-9 [19963390.001]
  • (PMID = 20189399.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Corrected and Republished Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Membrane Glycoproteins; 0 / Plant Extracts; 0 / RNA, Messenger; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse; EC 1.14.18.1 / Monophenol Monooxygenase; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


52. Yun CY, Kim D, Lee WH, Park YM, Lee SH, Na M, Jahng Y, Hwang BY, Lee MK, Han SB, Kim Y: Torilin from Torilis japonica inhibits melanin production in alpha-melanocyte stimulating hormone-activated B16 melanoma cells. Planta Med; 2009 Nov;75(14):1505-8
Hazardous Substances Data Bank. ARBUTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Torilin from Torilis japonica inhibits melanin production in alpha-melanocyte stimulating hormone-activated B16 melanoma cells.
  • Torilin dose-dependently inhibited melanin production, with an IC(50) value of 25 microM, in alpha-melanocyte stimulating hormone (alpha-MSH)-activated B16 melanoma cells.
  • [MeSH-major] Apiaceae / chemistry. Dermatologic Agents / pharmacology. Melanins / biosynthesis. Melanoma, Experimental. Plant Extracts / pharmacology. Skin Pigmentation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19533579.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Melanins; 0 / Plant Extracts; 0 / Sesquiterpenes, Guaiane; 0 / torilin; 581-05-5 / alpha-MSH; C5INA23HXF / Arbutin; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


53. Lv N, Koo JH, Yoon HY, Yu J, Kim KA, Choi IW, Kwon KB, Kwon KS, Kim HU, Park JW, Park BH: Effect of Angelica gigas extract on melanogenesis in B16 melanoma cells. Int J Mol Med; 2007 Nov;20(5):763-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Angelica gigas extract on melanogenesis in B16 melanoma cells.
  • During the screening of herbs for inhibition of melanogenesis, it was observed that ethanolic extract of Angelicae Gigantis Radix (AGE) effectively inhibited isobutylmethylxanthine-induced melanogenesis in B16 melanoma cells.
  • [MeSH-major] Apiaceae / chemistry. Melanins / biosynthesis. Melanoma / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912471.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Melanins; 0 / Plant Extracts; 0 / RNA, Messenger; 1F7A44V6OU / Colforsin; 581-05-5 / alpha-MSH; EC 1.14.18.1 / Monophenol Monooxygenase; TBT296U68M / 1-Methyl-3-isobutylxanthine
  •  go-up   go-down


54. Yang Z, Cox JL: Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int; 2007;7:8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin L increases invasion and migration of B16 melanoma.
  • METHODS: We have examined the role of cathepsin L in highly metastatic B16F10 murine melanoma cells through genetic antisense constructs of cathepsin L.
  • The effects of cathepsin L antisense were examined for melanoma cell proliferation, invasion, migration and adhesion.
  • Cathepsin L contributed to melanoma cell invasion and also augmented melanoma cell migration.
  • Finally, the inhibition of melanoma cell migration via down-regulation of cathepsin L appears to be independent of cystatin C expression.
  • CONCLUSION: This study shows that cathepsin L facilitates high metastatic B16 melanoma cell invasion and migration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Mar 1;91(5):972-82 [11251949.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2282-91 [11147599.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4070-6 [10945612.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):787-95 [10762753.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):633-9 [16465367.001]
  • [Cites] Melanoma Res. 1999 Aug;9(4):369-74 [10504055.001]
  • [Cites] Eur J Cell Biol. 1997 Nov;74(3):294-301 [9402478.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):559-67 [10100707.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2733-6 [9661883.001]
  • [Cites] Biol Chem. 1998 Feb;379(2):131-5 [9524064.001]
  • [Cites] Melanoma Res. 1997 Apr;7(2):97-101 [9167174.001]
  • [Cites] Protein Profile. 1995;2(14):1581-643 [8771190.001]
  • [Cites] Eur J Cancer. 1995;31A(5):661-4 [7640035.001]
  • [Cites] Physiol Rev. 1993 Jan;73(1):161-95 [8419965.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3610-4 [1617632.001]
  • [Cites] Melanoma Res. 1992 Jan-Feb;1(5-6):333-40 [1422189.001]
  • [Cites] Mol Carcinog. 1992;5(3):238-45 [1586450.001]
  • [Cites] Cancer Res. 1989 Jul 1;49(13):3553-7 [2731177.001]
  • [Cites] Biochem J. 1987 Sep 15;246(3):731-5 [3689328.001]
  • [Cites] J Mol Evol. 1986;23(1):11-22 [3084797.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4870-5 [2758418.001]
  • [Cites] Biochim Biophys Acta. 1990 Jun 21;1049(2):99-125 [1694695.001]
  • [Cites] Anal Biochem. 1972 May;47(1):184-92 [5031110.001]
  • [Cites] Pancreas. 2004 Oct;29(3):204-11 [15367886.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34827-32 [15197181.001]
  • [Cites] Mol Cell. 2004 Apr 23;14(2):207-19 [15099520.001]
  • [Cites] Arch Dermatol Res. 2004 Mar;295(10):411-21 [14767779.001]
  • [Cites] Mol Cancer Res. 2004 Mar;2(3):183-95 [15037657.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):146-51 [14729618.001]
  • [Cites] Cancer Gene Ther. 2001 Jul;8(7):522-8 [11498774.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):185-90 [12359367.001]
  • [Cites] Cancer Gene Ther. 2003 Feb;10(2):141-51 [12536203.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S46-58 [14600592.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] J Cell Sci. 2003 Nov 1;116(Pt 21):4409-17 [13130092.001]
  • (PMID = 17488522.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1885792
  •  go-up   go-down


55. Sato K, Takahashi H, Iraha R, Toriyama M: Down-regulation of tyrosinase expression by acetylsalicylic acid in murine B16 melanoma. Biol Pharm Bull; 2008 Jan;31(1):33-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of tyrosinase expression by acetylsalicylic acid in murine B16 melanoma.
  • Therefore, we investigated the effect of ASA on melanin production using B16 murine melanoma cells and demonstrated a new biological effect of ASA.
  • In the presence of alpha-melanocyte stimulating hormone (alpha-MSH), B16 melanoma cells are stimulated to enhance melanin synthesis.
  • ASA (2 mM) inhibited alpha-MSH-enhanced melanin synthesis in melanoma more strongly than other well-known anti-melanogenic agents such as arbutin (2 mM) and kojic acid (200 microM).
  • [MeSH-major] Aspirin / pharmacology. Melanoma, Experimental / enzymology. Monophenol Monooxygenase / antagonists & inhibitors

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18175938.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Melanins; 63-84-3 / Dihydroxyphenylalanine; EC 1.14.18.1 / Monophenol Monooxygenase; R16CO5Y76E / Aspirin
  •  go-up   go-down


56. Sato K, Morita M, Ichikawa C, Takahashi H, Toriyama M: Depigmenting mechanisms of all-trans retinoic acid and retinol on B16 melanoma cells. Biosci Biotechnol Biochem; 2008 Oct;72(10):2589-97
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depigmenting mechanisms of all-trans retinoic acid and retinol on B16 melanoma cells.
  • We assessed the effects of ATRA and retinol on melanogenesis in murine B16 melanoma cells.
  • In the present study, ATRA and retinol inhibited melanin synthesis in melanoma cells stimulated by alpha-melanocyte stimulating hormone (alpha-MSH) or 3-isobutyl-1-methylxanthine (IBMX).
  • [MeSH-major] Melanoma / metabolism. Pigmentation / drug effects. Tretinoin / pharmacology. Vitamin A / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838813.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Melanins; 11103-57-4 / Vitamin A; 5688UTC01R / Tretinoin; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


57. Matsuda H, Hirata N, Kawaguchi Y, Naruto S, Takata T, Oyama M, Iinuma M, Kubo M: Melanogenesis stimulation in murine B16 melanoma cells by Kava (Piper methysticum) rhizome extract and kavalactones. Biol Pharm Bull; 2006 Apr;29(4):834-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanogenesis stimulation in murine B16 melanoma cells by Kava (Piper methysticum) rhizome extract and kavalactones.
  • Melanogenesis stimulation activity of aqueous ethanolic extracts obtained from several different parts of five Piper species, namely Piper longum, P. kadsura, P. methysticum, P. betle, and P. cubeba, were examined by using cultured murine B16 melanoma cells.
  • 7,8-Epoxyyangonin (5) showed a significant stimulatory effect on melanogenesis in B16 melanoma cells.
  • [MeSH-major] Kava / chemistry. Melanins / biosynthesis. Melanoma, Experimental / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595931.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Lactones; 0 / Melanins; 0 / Plant Extracts
  •  go-up   go-down


58. Arung ET, Yoshikawa K, Shimizu K, Kondo R: Isoprenoid-substituted flavonoids from wood of Artocarpus heterophyllus on B16 melanoma cells: cytotoxicity and structural criteria. Fitoterapia; 2010 Mar;81(2):120-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoprenoid-substituted flavonoids from wood of Artocarpus heterophyllus on B16 melanoma cells: cytotoxicity and structural criteria.
  • A structure-activity investigation of the effect of these isolated compounds (1-9) and structurally related compounds on B16 melanoma cells indicated that isoprenoid moiety substitutions in flavonoids enhance their cytotoxicity, and that the position of attachment and the number of isoprenoid-substituent moieties per molecule influence flavonoid cytotoxicity.
  • [MeSH-major] Artocarpus / chemistry. Flavonoids / pharmacology. Melanoma, Experimental / drug therapy. Plant Extracts / pharmacology. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19686821.001).
  • [ISSN] 1873-6971
  • [Journal-full-title] Fitoterapia
  • [ISO-abbreviation] Fitoterapia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Plant Extracts; 0 / Terpenes
  •  go-up   go-down


59. Chen J, Peng H, Ou-Yang X, He X: Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res; 2008 Oct;18(5):322-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells.
  • To further explore the antitumor function of Rg3, we investigated the in-vitro and in-vivo activity of Rg3 in the treatment of B16 melanoma cells, derived from C57BL/6 mouse, capable of forming tumor colonies in the lungs following intravenous injection.
  • B16 melanoma-bearing mice were used to evaluate in vivo the antitumor activity of Rg3.
  • This research might supply valuable data for chemotherapy with Rg3 in melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Proliferation / drug effects. Ginsenosides / therapeutic use. Lung Neoplasms / drug therapy. Melanoma, Experimental / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781130.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ginsenosides; 0 / Proto-Oncogene Proteins c-bcl-2; 14197-60-5 / ginsenoside Rg3; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


60. Hongo T, Miyano-Kurosaki N, Kurosaki K, Hata A, Harigae S, Tomoda A: 2-aminophenoxazine-3-one prevents pulmonary metastasis of mouse B16 melanoma cells in mice. J Pharmacol Sci; 2010;114(1):63-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-aminophenoxazine-3-one prevents pulmonary metastasis of mouse B16 melanoma cells in mice.
  • 2-Aminophenoxazine-3-one (Phx-3) induced cellular apoptosis in mouse melanoma B16 cells as detected by DNA laddering and upregulated Fas expression in the cells in vitro.
  • When B16 melanoma cells were injected into the tail veins of mice, significant metastasis of the cells was indicated in the lungs, 14 days after treatment.
  • In contrast, when 0.5 mg/kg Phx-3 was administered to mice through the tail veins, once simultaneously with or every three days after the administration of B16 melanoma cells, the number of metastasized pulmonary cells was extremely reduced.
  • The present results indicate that the metastasis of mouse B16 melanoma cells to the lung was significantly inhibited in mice administered Phx-3, which activated the intrinsic and extrinsic apoptotic pathways.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Melanoma, Experimental / prevention & control. Melanoma, Experimental / secondary. Oxazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20710120.001).
  • [ISSN] 1347-8648
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oxazines; 1916-59-2 / 3-aminophenoxazone
  •  go-up   go-down


61. D'Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E: Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol; 2005 Jul;5(7-8):1205-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.
  • We report that OM-174, a purified water soluble diphosphorylated and triacetylated lipid A derived from E. coli, is able to reduce tumour progression and to prolong the survival of mice in the B16 melanoma experimental model.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Lipopolysaccharides / therapeutic use. Melanoma, Experimental / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914325.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipopolysaccharides; 8N3DW7272P / Cyclophosphamide; HC3530GGGG / defoslimod
  •  go-up   go-down


62. Kim KS, Kim JA, Eom SY, Lee SH, Min KR, Kim Y: Inhibitory effect of piperlonguminine on melanin production in melanoma B16 cell line by downregulation of tyrosinase expression. Pigment Cell Res; 2006 Feb;19(1):90-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of piperlonguminine on melanin production in melanoma B16 cell line by downregulation of tyrosinase expression.
  • In the present study, piperlonguminine from Piper longum was discovered to inhibit melanin production in melanoma B16 cells stimulated with alpha-melanocyte stimulating hormone (alpha-MSH), 3-isobutyl-1-methylxanthine or protoporphyrin IX, where the compound exhibited stronger depigmenting efficacy than kojic acid.
  • Surprisingly, piperlonguminine did not inhibit the catalytic activity of cell-free tyrosinase from melanoma B16 cells but rather suppressed tyrosinase mRNA expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420250.001).
  • [ISSN] 0893-5785
  • [Journal-full-title] Pigment cell research
  • [ISO-abbreviation] Pigment Cell Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / Diglycerides; 0 / Dioxolanes; 0 / Melanins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Phosphodiesterase Inhibitors; 0 / Plant Extracts; 0 / Protoporphyrins; 0 / RNA, Messenger; 553-12-8 / protoporphyrin IX; 581-05-5 / alpha-MSH; 86390-77-4 / 1-oleoyl-2-acetylglycerol; EC 1.14.18.1 / Monophenol Monooxygenase; HN39MC8KIO / piperlonguminine; TBT296U68M / 1-Methyl-3-isobutylxanthine
  •  go-up   go-down


63. Meyer S, Hafner C, Guba M, Flegel S, Geissler EK, Becker B, Koehl GE, Orsó E, Landthaler M, Vogt T: Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol; 2005 Nov;27(5):1197-206
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells.
  • We have previously shown that ephrin-B2 mRNA is overexpressed in advanced malignant melanomas (MM).
  • Using a wild-type ephrin-B2-negative B16 mouse MM subclone we show that overexpression of ephrin-B2 leads to the formation of multiple lamellipodia, enhanced polymerisation of actin fibers, and induction of focal adhesion complexes with constitutive activation of focal adhesion kinase.
  • Consequently, ephrin-B2-overexpressing B16 cells display a significant increase of beta1-integrin-mediated attachment to matrix components, preferentially laminin and fibronectin.
  • [MeSH-major] Ephrin-B2 / biosynthesis. Extracellular Matrix / physiology. Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211213.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ephrin-B2
  •  go-up   go-down


64. Zhao Y, Liu J, McMartin KE: Inhibition of NADPH oxidase activity promotes differentiation of B16 melanoma cells. Oncol Rep; 2008 May;19(5):1225-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of NADPH oxidase activity promotes differentiation of B16 melanoma cells.
  • The activity of NADPH oxidase is increased in malignant skin keratinocytes.
  • We demonstrated that inhibition of NADPH oxidase activity by diphenyleneiodonium (DPI) suppressed free radical production, inhibited cell growth and promoted cell differentiation of B16 melanoma cells, as indicated by cell morphology, increased production of melanin, and increased expression of microphthalmia-associated transcription factor (MITF).
  • In addition, the protein levels of the tumor suppressor p53 were suppressed by DPI, suggesting that p53 is activated by oxidative stress and may negatively regulate differentiation in melanoma cells.
  • Taken together, these results suggest that inhibiting NADPH oxidase activity promotes cell differentiation of B16 melanoma cells.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Differentiation. Enzyme Activation. Enzyme Inhibitors / pharmacology. Extracellular Signal-Regulated MAP Kinases / metabolism. Melanins / metabolism. Melanoma, Experimental. Mice. Microphthalmia-Associated Transcription Factor / biosynthesis. RNA, Small Interfering / metabolism. Reactive Oxygen Species. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425380.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Melanins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Mitf protein, mouse; 0 / RNA, Small Interfering; 0 / Reactive Oxygen Species; 0 / Tumor Suppressor Protein p53; EC 1.6.3.1 / NADPH Oxidase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


65. Voigt H, Houben R, Schrama D, Hofmann UB, Vetter-Kauczok CS, Becker JC: Matrix metalloproteinase induction in the tumor stroma does not depend on CD147 expression in murine B16 melanoma. Tumour Biol; 2007;28(4):229-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase induction in the tumor stroma does not depend on CD147 expression in murine B16 melanoma.
  • METHODS AND RESULTS: To address the impact of CD147 on MMP expression in the murine B16 melanoma model, we consequently stably knocked down CD147 expression in two B16 sublines.
  • Coculture of melanoma cells with different fibroblast cell lines demonstrated that neither CD147+ nor CD147- B16 tumor cells altered the expression of MMP-2 or MMP-9 by the fibroblasts, although we could confirm the susceptibility of these fibroblasts for MMP induction.
  • CONCLUSIONS: At least for the murine B16 melanoma model, CD147 expression on tumor cells seems not to be crucial for MMP-2, MMP-9 and MT1-MMP induction on tumor-associated stromal cells.
  • [MeSH-major] Antigens, CD147 / biosynthesis. Gene Expression Regulation, Neoplastic. Matrix Metalloproteinases / biosynthesis. Melanoma, Experimental / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709990.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 136894-56-9 / Antigens, CD147; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


66. Sato K, Toriyama M: Effect of pyrroloquinoline quinone (PQQ) on melanogenic protein expression in murine B16 melanoma. J Dermatol Sci; 2009 Feb;53(2):140-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of pyrroloquinoline quinone (PQQ) on melanogenic protein expression in murine B16 melanoma.
  • OBJECTIVE: In this study, we assessed the effects of PQQ on melanogenic protein expression of murine B16 melanoma cells.
  • METHODS: We assessed melanin production of PQQ-treated B16 melanoma cells.
  • RESULTS: In the present study, PQQ inhibited melanin synthesis in cultured melanoma cells stimulated by either alpha-melanocyte stimulating hormone (alpha-MSH) or 3-isobutyl-1-methylxanthine (IBMX).
  • [MeSH-major] Melanins / biosynthesis. Melanoma, Experimental / enzymology. Monophenol Monooxygenase / metabolism. PQQ Cofactor / pharmacology. Pigmentation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013771.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Melanins; 0 / Membrane Glycoproteins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Mitf protein, mouse; 0 / RNA, Messenger; 581-05-5 / alpha-MSH; 72909-34-3 / PQQ Cofactor; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse; EC 1.14.18.1 / Monophenol Monooxygenase; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase; TBT296U68M / 1-Methyl-3-isobutylxanthine
  •  go-up   go-down


67. Song HS, Sim SS: Acteoside inhibits alpha-MSH-induced melanin production in B16 melanoma cells by inactivation of adenyl cyclase. J Pharm Pharmacol; 2009 Oct;61(10):1347-51
MedlinePlus Health Information. consumer health - Antioxidants.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acteoside inhibits alpha-MSH-induced melanin production in B16 melanoma cells by inactivation of adenyl cyclase.
  • METHODS: We used tyrosinase activity and melanin production stimulated in B16 melanoma cells by alpha-melanocyte stimulating hormone (alpha-MSH) or forskolin to measure the whitening effect of acteoside.
  • KEY FINDINGS: Acteoside did not directly inhibit mushroom tyrosinase activity, but dose-dependently inhibited tyrosinase activity and melanin production in B16 melanoma cells stimulated by 1 micromol/l alpha-MSH.
  • [MeSH-major] Adenylyl Cyclases / drug effects. Antioxidants / pharmacology. Glucosides / pharmacology. Melanoma, Experimental / enzymology. Phenols / pharmacology. alpha-MSH / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19814867.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biphenyl Compounds; 0 / Glucosides; 0 / Melanins; 0 / Phenols; 0 / Picrates; 0 / Reactive Oxygen Species; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl; 1F7A44V6OU / Colforsin; 581-05-5 / alpha-MSH; 61276-17-3 / acteoside; E0399OZS9N / Cyclic AMP; EC 1.14.18.1 / Monophenol Monooxygenase; EC 4.6.1.1 / Adenylyl Cyclases
  •  go-up   go-down


68. Ohshima Y, Tsukimoto M, Takenouchi T, Harada H, Suzuki A, Sato M, Kitani H, Kojima S: gamma-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta; 2010 Jan;1800(1):40-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] gamma-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells.
  • Here, we examined gamma-irradiation-induced ATP release and its mechanism in B16 melanoma.
  • To investigate mechanism of radiation-induced ATP release, we pharmacologically inhibited the ATP release and established stable P2X(7) receptor-knockdown B16 melanoma cells using two short hairpin RNAs targeting P2X(7) receptor.
  • Our results indicate that gamma-irradiation evokes ATP release from melanoma cells, and P2X(7) receptor channel plays a significant role in mediating the ATP release.
  • [MeSH-minor] Animals. Cell Line, Tumor. Extracellular Space / drug effects. Extracellular Space / metabolism. Extracellular Space / radiation effects. Immunoblotting. Melanoma, Experimental / genetics. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Purinergic P2 Receptor Antagonists. RNA Interference. Receptors, Purinergic P2X7. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19854240.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Purinergic P2 Receptor Antagonists; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


69. Wang P, Yang X, Wu P, Zhang J, Sato T, Yamagata S, Yamagata T: GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells. Oncology; 2007;73(5-6):430-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells.
  • OBJECTIVE: We have previously shown GM3 to positively regulate TNF-alpha expression via a PI3K/Akt pathway in mouse melanoma B16 cells [Wang et al.: Biochem Biophys Res Commun 2007;356:438-443].
  • RESULTS: PI3K inhibitors LY294002 and LY303511 were shown to suppress TNF-alpha expression that is stimulated by GM3 in B16 cells, suggesting that the GM3 signal is located upstream of the PI3K-Akt pathway.
  • CONCLUSIONS: The GM3 signal is thus transduced in B16 cells through a PI3K, Rictor/mTOR, Akt, Arhgdib pathway, leading to stimulated expression of TNF-alpha.
  • [MeSH-major] Carrier Proteins / physiology. G(M3) Ganglioside / pharmacology. Gene Expression Regulation, Neoplastic. Melanoma, Experimental / genetics. Tumor Necrosis Factor-alpha / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18523362.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Chromones; 0 / DNA Primers; 0 / G(M3) Ganglioside; 0 / Piperazines; 0 / RNA, Small Interfering; 0 / Rhog protein, mouse; 0 / Tumor Necrosis Factor-alpha; 0 / rictor protein, mouse; 154447-38-8 / LY 303511; EC 3.6.1.- / GTP Phosphohydrolases
  •  go-up   go-down


70. Hirata N, Naruto S, Ohguchi K, Akao Y, Nozawa Y, Iinuma M, Matsuda H: Mechanism of the melanogenesis stimulation activity of (-)-cubebin in murine B16 melanoma cells. Bioorg Med Chem; 2007 Jul 15;15(14):4897-902
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of the melanogenesis stimulation activity of (-)-cubebin in murine B16 melanoma cells.
  • (-)-Cubebin showed a melanogenesis stimulation activity in a concentration-dependent manner in murine B16 melanoma cells without any significant effects on cell proliferation.
  • Tyrosinase activity was increased at 24-72 h after addition of cubebin to B16 cells, and then intracellular melanin amount was increased at 48-96 h after the treatment.
  • SB203580, a selective inhibitor of p38 MAPK, completely blocked cubebin-induced expression of tyrosinase mRNA in B16 cells.
  • These results suggested that cubebin increased melanogenesis in B16 cells through the enhancement of tyrosinase expression mediated by activation of p38 MAPK.
  • [MeSH-major] Lignans / pharmacology. Melanins / biosynthesis. Melanoma / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17521910.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Lignans; 0 / Melanins; 0 / Pyridines; 0 / RNA, Messenger; 0 / SB 203580; EC 1.14.18.1 / Monophenol Monooxygenase; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; J237078S8A / cubebin
  •  go-up   go-down


71. Mena S, Benlloch M, Ortega A, Carretero J, Obrador E, Asensi M, Petschen I, Brown BD, Estrela JM: Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease. Clin Cancer Res; 2007 May 1;13(9):2658-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease.
  • PURPOSE: Advanced melanoma resists all current therapies, and metastases in the liver are particularly problematic.
  • Prevalent resistance factors include elevated glutathione (GSH) and increased expression of bcl-2 in melanoma cells.
  • This study determined the in vivo efficacy of combination therapies administered while GSH and Bcl-2 were individually and simultaneously decreased in metastatic melanoma lesions.
  • EXPERIMENTAL DESIGN: Highly metastatic murine B16 melanoma (B16M-F10) cells have elevated levels of both GSH and Bcl-2.
  • CONCLUSIONS: Our results suggest a new strategy to induce regression of late-stage metastatic melanoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Glutathione / antagonists & inhibitors. Melanoma, Experimental / therapy. Paclitaxel / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Skin Neoplasms / therapy. Tumor Necrosis Factor-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. Glutamine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473197.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Thionucleotides; 0 / Tumor Necrosis Factor-alpha; 0RH81L854J / Glutamine; 85J5ZP6YSL / oblimersen; GAN16C9B8O / Glutathione; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


72. Ren Z, Ye X, Fang C, Lu Q, Zhao Y, Liu F, Liang M, Hu F, Chen HZ: Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response. Cancer Biol Ther; 2008 Feb;7(2):191-95
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
  • The HSP expression and cytopathic killing effect in mouse B16 melanoma and human PLC/PRF/5 hepatoma cells were measured after in vitro infection of adenoviruses.
  • Survival rate of immunocompetent C57/BL mice was observed following intratumor injection of recombinant adenoviruses in B16 melanoma xenograft models.
  • The Ad.CMV.HSP.IRES.E1a induced significantly higher HSP expression level than Ad.CMV.IRES.E1a in both B16 and PLC/ PRF/5 cells.
  • The cytocidal efficacy of Ad.CMV.HSP.IRES.E1a and Ad.CMV.IRES.E1a in PLC/PRF/5 cells was much higher than that in B16 cells, where the two adenoviruses showed similarly very weak oncolytic effect in vitro.
  • E1a improved animal survival rate and exhibited more potent anti-tumor efficiency than Ad.CMV.IRES.E1a in B16 xenograft models.
  • [MeSH-major] Genetic Therapy / methods. Genetic Vectors / administration & dosage. HSP70 Heat-Shock Proteins / genetics. Melanoma, Experimental / therapy. Oncolytic Virotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Feb;7(2):196-7 [18347427.001]
  • (PMID = 18073525.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / HSP70 Heat-Shock Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


73. Qin YS, Zhang X, Li L, Yu HL: [Effect of histamine on metastasis of melanoma B16 cell xenograft in C57BL/6 mice]. Ai Zheng; 2007 Aug;26(8):833-6
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of histamine on metastasis of melanoma B16 cell xenograft in C57BL/6 mice].
  • METHODS: Cultured melanoma B16 cells were inoculated into the left armpit of C57BL/6 mice to develop melanoma.
  • RESULTS: All the mice developed melanoma after inoculation.
  • CONCLUSION: Histamine can inhibit the metastasis of melanoma B16 cells in C57BL/6 mice either through lymphatic or hemal route, and this partly because of its inhibitory effect on tumor growth.
  • [MeSH-major] Histamine / pharmacology. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Melanoma, Experimental / pathology. Splenic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697542.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 820484N8I3 / Histamine
  •  go-up   go-down


74. Murakami M, Matsuzaki F, Funaba M: Regulation of melanin synthesis by the TGF-beta family in B16 melanoma cells. Mol Biol Rep; 2009 Jul;36(6):1247-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of melanin synthesis by the TGF-beta family in B16 melanoma cells.
  • Effects of representative members of the transforming growth factor-beta (TGF-beta) family, TGF-beta1, activin A and BMP-2, on melanin content and expression of pigment-producing enzymes were examined in B16 melanoma cells.
  • As compared with parental B16 cells, the inhibitory effects of TGF-beta1 and activin A on melanin content were relative smaller in B16 F10 cells, a subline of B16 cells that contain more pigment.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Melanins / biosynthesis. Melanocyte-Stimulating Hormones / pharmacology. Melanoma / metabolism. Transforming Growth Factor beta / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18600473.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / Melanins; 0 / Membrane Glycoproteins; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / activin A; 104625-48-1 / Activins; 9002-79-3 / Melanocyte-Stimulating Hormones; EC 1.- / Oxidoreductases; EC 1.14.18.- / TYRP1 protein, human; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


75. Penafuerte C, Galipeau J: TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother; 2008 Aug;57(8):1197-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect.
  • We have previously described a Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin 2 (IL2) fusokine (aka GIFT2) which serves as a potent anticancer cytokine and it here served as a means to understand the mechanistic underpinnings to the immune bystander effect in an immune competent model of B16 melanoma.
  • As expected, we observed that GIFT2 secreted by genetically engineered B16 tumor cells induces a bystander effect on non modified B16 cells, when admixed in a 1:1 ratio.
  • However, despite keeping the 1:1 ratio constant, the immune bystander effect was completely lost as the total B16 cell number was increased from 10(4) to 10(6) which correlated with a sharp reduction in the number of tumor-infiltrating NK cells.
  • We found that B16 secrete biologically active TGFbeta which in turn inhibited GIFT2 dependent immune cell proliferation in vitro and downregulated IL-2R beta expression and IFN gamma secretion by NK cells.
  • In vivo blockade of B16 originating TGFbeta significantly improved the immune bystander effect arising from GIFT2.
  • [MeSH-major] Bystander Effect / immunology. Genetic Therapy / methods. Immunotherapy. Melanoma, Experimental / immunology. Melanoma, Experimental / therapy. Transforming Growth Factor beta / immunology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18214474.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II; 0 / Interleukin-2; 0 / Interleukin-2 Receptor beta Subunit; 0 / Transforming Growth Factor beta; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


76. Matsuda H, Hirata N, Kawaguchi Y, Yamazaki M, Naruto S, Shibano M, Taniguchi M, Baba K, Kubo M: Melanogenesis stimulation in murine b16 melanoma cells by umberiferae plant extracts and their coumarin constituents. Biol Pharm Bull; 2005 Jul;28(7):1229-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanogenesis stimulation in murine b16 melanoma cells by umberiferae plant extracts and their coumarin constituents.
  • ) CUSSON and C. formosanum YABE, were examined by using cultured murine B16 melanoma cells.
  • The melanogenesis stimulatory effects of sixteen coumarins (1-16) isolated from the seven Umbelliferae crude drugs were also examined.
  • [MeSH-major] Apiaceae / chemistry. Coumarins / pharmacology. Melanins / biosynthesis. Melanoma, Experimental / metabolism. Plant Extracts / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997104.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coumarins; 0 / Melanins; 0 / Plant Extracts
  •  go-up   go-down


77. Fëdorov ES, Manikhas GM, Petrishchëv NN, Dubina MV: [The role of gap junction communication in metastatic B16 melanoma in C57BL mice]. Vopr Onkol; 2006;52(4):433-7
Hazardous Substances Data Bank. (Z)-9-OCTADECENAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of gap junction communication in metastatic B16 melanoma in C57BL mice].
  • The study is concerned with the effects of non-specific blocking gap junction communication with oleamide as well as genesis and spreading of melanoma B16 metastases to the lung in mice C57B1.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinogens. Cell Communication. Gap Junctions. Melanoma, Experimental / ultrastructure. Oleic Acids / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024817.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinogens; 0 / Oleic Acids; 7L25QK8BWO / oleylamide
  •  go-up   go-down


78. Hao S, Ye Z, Li F, Meng Q, Qureshi M, Yang J, Xiang J: Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp Oncol; 2006 Jun;28(2):126-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes.
  • METHODS: The highly metastatic B16 melanoma cell line (BL6-10) was generated in our laboratory.
  • For phenotypic analysis BL6-10 and F1 melanoma cells were stained with FITC-conjugated anti-MHC I (H-2K(b)), MHC II (Ia(b)) and Met 72 antibodies and analyzed by flow cytometry.
  • C57BL/6 mice (8 per group) were injected (i. v.) with 0.5 x 10(6) F1, BL6-10 and F1(EXO) melanoma cells.
  • All mice inoculated with BL6-10 melanoma cells had numerous lung tumor colonies, while mice injected with F1 tumor cells were free of lung metastatic colonies.
  • [MeSH-major] Cytoplasmic Vesicles / transplantation. Lung Neoplasms / secondary. Melanoma, Experimental / pathology. Skin Neoplasms / pathology


79. Thanigaimalai P, Hoang TA, Lee KC, Bang SC, Sharma VK, Yun CY, Roh E, Hwang BY, Kim Y, Jung SH: Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells. Bioorg Med Chem Lett; 2010 May 1;20(9):2991-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells.
  • In order to define the structural requirements of phenylthiourea (PTU), a series of thiourea and thiosemicarbazone analogs were prepared and evaluated as inhibitors of melanogenesis in melanoma B16 cells.
  • [MeSH-major] Benzaldehydes / chemistry. Melanoma, Experimental / drug therapy. Peptides / chemistry. Phenylthiourea / chemistry. Thiosemicarbazones / chemistry

  • Hazardous Substances Data Bank. BENZALDEHYDE .
  • Hazardous Substances Data Bank. 1-PHENYL-2-THIOUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Ltd.
  • (PMID = 20359890.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-(4-tert-butylbenzylidene)hydrazinecarbothioamide; 0 / Benzaldehydes; 0 / Peptides; 0 / Thiosemicarbazones; 6F82C6Q54C / Phenylthiourea; EC 1.14.18.1 / Monophenol Monooxygenase; TA269SD04T / benzaldehyde
  •  go-up   go-down


80. Berezhnaya NM, Vinnichuk YD, Belova OB: The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin. Exp Oncol; 2008 Mar;30(1):52-5
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
  • AIM: To study the influence of doxorubicin at low doses on antitumor action of activated (LAK) and non-activated lymphocytes from lymph nodes toward tumor cells of mice bearing doxorubicin-resistant and doxorubicin-sensitive transplantable MC-rhabdomyosarcoma and B16 melanoma.
  • MATERIALS AND METHODS: The study was carried out on BALB/c mice bearing MC-rhabdomyosarcoma and 57BL/6 mice bearing 16 melanoma.
  • RESULTS: At the day 7 of tumor growth in mice bearing resistant MC-rhabdomyosarcoma, non-activated lymphocytes pretreated with low-dose doxorubicin possess the highest antitumor activity, and in mice bearing doxorubicin-resistant B16 melanoma the highest antitumor activity was detected for lymphocytes after combined cultivation with IL-2 and doxorubicin.
  • At the day 14 of tumor growth, LAK obtained from lymphocytes pretreated with doxorubicin possess the highest cytotoxic activity toward resistant tumor cells both of MC-rhabdomyosarcoma and B16 melanoma.
  • CONCLUSION: To elevate antitumor activity of LAK toward MC-rhabdomyosarcoma and B16 melanoma cells, low doses of doxorubicin could be used at certain conditions of LAK generation.
  • [MeSH-major] Doxorubicin / administration & dosage. Drug Resistance, Neoplasm / drug effects. Killer Cells, Lymphokine-Activated / drug effects. Lymphocyte Activation / drug effects. Melanoma, Experimental / drug therapy. Rhabdomyosarcoma / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438341.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


81. Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, Carretero J, Estrela JM: Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem; 2005 Feb 25;280(8):6950-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity.
  • Highly metastatic B16 melanoma (B16M)-F10 cells, as compared with the low metastatic B16M-F1 line, have higher GSH content and preferentially overexpress BCL-2.
  • [MeSH-major] Apoptosis. Endothelium / cytology. Glutathione / metabolism. Melanoma, Experimental / pathology. Neoplasm Metastasis. gamma-Glutamyltransferase / antagonists & inhibitors

  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15561710.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / multidrug resistance-associated protein 1; 126880-72-6 / Cystic Fibrosis Transmembrane Conductance Regulator; CJ0O37KU29 / Verapamil; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione
  •  go-up   go-down


82. Sun T, Sun BC, Ni CS, Zhao XL, Wang XH, Qie S, Zhang DF, Gu Q, Qi H, Zhao N: Pilot study on the interaction between B16 melanoma cell-line and bone-marrow derived mesenchymal stem cells. Cancer Lett; 2008 May 8;263(1):35-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study on the interaction between B16 melanoma cell-line and bone-marrow derived mesenchymal stem cells.
  • Our previous study had shown that BMSCs maybe participate in angiogenesis in melanoma in vivo.
  • The aim of this study was to investigate the interaction between B16 melanoma cells and BMSCs in vitro, the mechanism of BMSCs participating in melanoma angiogenesis in vivo is unclear, so a co-culture system containing BMSCs and B16 melanoma cells, based on transwell indirect model, was established, and the interaction between BMSCs and B16 melanoma cells was studied in vitro.
  • In our study, BMSCs were generated out of bone marrow from C57 mouse, isolated BMSCs were positive for the markers CD105, CD90, CD73, CD44 and CD166 and negative for endothelial markers, which acquired endothelial phenotype (including the expression of VEGFR-1, VEGFR-2, Factor VIII) after co-culture with B16 melanoma cells; at the same time, B16 melanoma cells also up-regulated the expression of VEGF-a, VEGFR-1, VEGFR-2 and Factor VIII.
  • The proliferation rate of B16 melanoma cells and BMSCs were also found to be increased.
  • [MeSH-major] Bone Marrow Cells / cytology. Melanoma, Experimental / pathology. Mesenchymal Stromal Cells / cytology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234417.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


83. Sitabkhan Y, Frankfater A: Differences in the expression of cathepsin B in B16 melanoma metastatic variants depend on transcription factor Sp1. DNA Cell Biol; 2007 Sep;26(9):673-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the expression of cathepsin B in B16 melanoma metastatic variants depend on transcription factor Sp1.
  • Cathepsin B contributes to the invasiveness of B16 melanoma cells in mice, with the highly metastatic B16a melanoma producing six- to eightfold more cathepsin B mRNA and protein than the less metastatic B16F1 variant.
  • The proximal promoter region of the cathepsin B (Ctsb) gene (-149 to +94) was previously found to be capable of reproducing this pattern of differential gene activation in B16 melanoma variants.
  • The binding of B16 melanoma nuclear proteins to this promoter region has now been mapped to three GC-boxes (Sp1 transcription factor binding sites) and a potential X-box [tax response element (TRE)/c-AMP responsive element (CRE) site].
  • Promoter activity was also attenuated by mutations within the GC-rich segment between +6 and +16, but not by mutation of the putative X-box.
  • Thus, the difference in cathepsin B expression between high and low metastatic B16 melanoma variants is largely due to different levels of Sp1.
  • [MeSH-major] Cathepsin B / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Melanoma, Experimental / genetics. Sp1 Transcription Factor / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691867.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Sp1 Transcription Factor; 148710-94-5 / Sp3 Transcription Factor; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


84. Lavi G, Voronov E, Dinarello CA, Apte RN, Cohen S: Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release; 2007 Nov 6;123(2):123-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases.
  • In vitro cytokine release and bioactivity studies in cultured melanoma B16 cells revealed the microspheres to be capable of sustained IL-1Ra release on a daily level that could inhibit cell proliferation for at least 7 days.
  • In mice injected with B16 melanoma cells, the sustained IL-1Ra delivery from biodegradable microspheres inhibited tumor growth and significantly prolonged mice survival.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Carriers. Interleukin 1 Receptor Antagonist Protein / pharmacology. Interleukin-1beta / antagonists & inhibitors. Lactic Acid / chemistry. Lung Neoplasms / prevention & control. Melanoma, Experimental / drug therapy. Microspheres. Polyglycolic Acid / chemistry. Polymers / chemistry

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17900737.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-1beta; 0 / Polymers; 0 / Recombinant Proteins; 0 / polylactic acid-polyglycolic acid copolymer; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


85. Itzhaki O, Skutelsky E, Kaptzan T, Siegal A, Sinai J, Schiby G, Michowitz M, Huszar M, Leibovici J: Decreased DNA ploidy may constitute a mechanism of the reduced malignant behavior of B16 melanoma in aged mice. Exp Gerontol; 2008 Mar;43(3):164-75
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased DNA ploidy may constitute a mechanism of the reduced malignant behavior of B16 melanoma in aged mice.
  • In the present study we report an incidentally found, not yet described mechanism, of the age-related reduced tumor progression, namely a decreased ploidy in B16 melanoma growing in old (near diploidy) as compared to young mice (tetraploidy).
  • Flow cytometry forward scatter data also showed a smaller cell size of melanoma cells from old mice.
  • DNA flow cytometry profile comparison demonstrated that while B16 melanoma cells from young animals contained a high percentage of tetraploid cells, those derived from old animals were mostly close to diploid.
  • The transit from tetraploidy to near euploidy in melanoma cells growing in aged mice might avoid the genetic instability inherent to tumor progression.
  • [MeSH-major] Aging / genetics. DNA, Neoplasm / analysis. Melanoma, Experimental / genetics. Ploidies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261868.001).
  • [ISSN] 0531-5565
  • [Journal-full-title] Experimental gerontology
  • [ISO-abbreviation] Exp. Gerontol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


86. Guan S, Su W, Wang N, Li P, Wang Y: A potent tyrosinase activator from Radix Polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells. Phytother Res; 2008 May;22(5):660-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A potent tyrosinase activator from Radix Polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells.
  • All the compounds were tested in B16 melanoma cells, the anthraquinones were found to inhibit cell proliferation at a concentration of 0.1-2.5 microg/mL, and THSG was found to be non-cytotoxic at a concentration of 0.1-12.5 microg/mL.
  • THSG significantly increased the activity of murine tyrosinase and stimulated melanin biosynthesis in B16 melanoma cells.
  • [MeSH-minor] Animals. Anthraquinones / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Glucosides / pharmacology. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Mice. Stilbenes / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389468.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2,3,5,4'-tetrahydroxystilbene-2-O-glucoside; 0 / Anthraquinones; 0 / Glucosides; 0 / Melanins; 0 / Plant Extracts; 0 / Stilbenes; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


87. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV: Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res; 2006 Apr 15;66(8):4468-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma.
  • We showed that, similar to their human orthologues, mIFN-lambda2 and mIFN-lambda3 signal through the IFN-lambda receptor complex, activate IFN stimulated gene factor 3, and are capable of inducing antiviral protection and MHC class I antigen expression in several cell types including B16 melanoma cells.
  • We then used the murine B16 melanoma model to investigate the potential antitumor activities of IFN-lambdas.
  • We developed B16 cells constitutively expressing murine IFN-lambda2 (B16.IFN-lambda2 cells) and evaluated their tumorigenicity in syngeneic C57BL/6 mice.
  • Although constitutive expression of mIFN-lambda2 in melanoma cells did not affect their proliferation in vitro, the growth of B16.IFN-lambda2 cells, when injected s.c. into mice, was either retarded or completely prevented.
  • We then developed IFN-lambda-resistant B16.IFN-lambda2 cells (B16.IFN-lambda2Res cells) and showed that their tumorigenicity was also highly impaired or completely abolished similar to B16.IFN-lambda2 cells, suggesting that IFN-lambdas engage host mechanisms to inhibit melanoma growth.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618774.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI051139; United States / NIAID NIH HHS / AI / R01 AI057468; United States / NIAID NIH HHS / AI / AI057468; United States / NIEHS NIH HHS / ES / ES05022
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Interferon; 9008-11-1 / Interferons
  •  go-up   go-down


88. Murad JM, de Souza LR, De Lucca FL: PKR activation by a non-coding RNA expressed in lymphocytes of mice bearing B16 melanoma. Blood Cells Mol Dis; 2006 Sep-Oct;37(2):128-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PKR activation by a non-coding RNA expressed in lymphocytes of mice bearing B16 melanoma.
  • In this study, we investigated the presence of ncRNAs in lymphocytes of C57BL/6 mice bearing B16 melanoma by using the differential display reverse transcription-PCR (DD-RT-PCR).
  • We detected a highly structured transcript of 220 nt with no open reading frame (ORF) which is able to activate PKR, and it is only expressed in lymphocytes of C57BL/6 mice bearing B16 melanoma.
  • [MeSH-major] Lymphocytes / metabolism. Melanoma, Experimental / metabolism. Neoplasms / metabolism. RNA, Untranslated / genetics. eIF-2 Kinase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857398.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Untranslated; EC 2.7.11.1 / eIF-2 Kinase
  •  go-up   go-down


89. Hou CC, Chen YP, Wu JH, Huang CC, Wang SY, Yang NS, Shyur LF: A galactolipid possesses novel cancer chemopreventive effects by suppressing inflammatory mediators and mouse B16 melanoma. Cancer Res; 2007 Jul 15;67(14):6907-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A galactolipid possesses novel cancer chemopreventive effects by suppressing inflammatory mediators and mouse B16 melanoma.
  • We investigated the cancer chemopreventive bioactivity of C. rabens phytocompounds in vitro and in vivo using cell- and gene-based bioassays and a mouse B16 melanoma model.
  • The bioactive glyceroglycolipid 1,2-di-O-alpha-linolenoyl-3-O-beta-galactopyranosyl-sn-glycerol (dLGG) that was identified from C. rabens was found in vitro and in vivo to be a potent nitric oxide (NO) scavenger. dLGG treatment inhibited both mRNA and protein expression of inducible NO synthase and cyclooxygenase-2 (COX-2) in murine macrophages and inhibited COX-2 gene transcription in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated B16 cells.
  • A dLGG-enriched extract from C. rabens (10 mg/kg) markedly suppressed B16 melanoma growth in C57BL/6J mice following i.p. administration, an effect comparable with that of cisplatin, a cancer chemotherapeutic drug.
  • [MeSH-minor] Active Transport, Cell Nucleus. Animals. Asteraceae / metabolism. Cell Survival. Female. I-kappa B Kinase / metabolism. Immunohistochemistry. Inhibitory Concentration 50. Macrophages / metabolism. Melanoma, Experimental. Mice. Mice, Inbred C57BL. Plant Extracts / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638902.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Galactolipids; 0 / Plant Extracts; EC 2.7.11.10 / I-kappa B Kinase
  •  go-up   go-down


90. Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM, Stewart CL, Kumar V, Mathew PA: Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol; 2005 Jan 15;174(2):800-7
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells.
  • To investigate the in vivo role of 2B4, wild-type and 2B4(-/-) mice were injected with CD48(+) and CD48(-) metastatic B16 melanoma cells.
  • Wild-type mice rejected CD48(+) melanoma poorly compared with CD48(-) tumor cells, suggesting that ligation of 2B4 by CD48 on melanoma cells is inhibitory.
  • In keeping with this, male 2B4(-/-) mice showed enhanced ability to reject CD48(+) melanoma cells.
  • However, female 2B4(-/-) mice poorly rejected both CD48(+) and CD48(-) melanoma cells, revealing a gender-specific and CD48-independent defect in mice lacking 2B4.
  • [MeSH-major] Antigens, CD / genetics. Graft Rejection / genetics. Graft Rejection / immunology. Killer Cells, Natural / immunology. Melanoma, Experimental / genetics. Melanoma, Experimental / immunology. Membrane Glycoproteins / deficiency. Membrane Glycoproteins / genetics. Receptors, Immunologic / deficiency. Receptors, Immunologic / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15634901.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA85753
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD48 antigen; 0 / Cd244 protein, mouse; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic
  •  go-up   go-down


91. Wu TG, Rose WA 2nd, Albrecht TB, Knutson EP, König R, Perdigão JR, Nguyen AP, Fleischmann WR Jr: IFN-alpha-induced murine B16 melanoma cancer vaccine cells: induction and accumulation of cell-associated IL-15. J Interferon Cytokine Res; 2007 Jan;27(1):13-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IFN-alpha-induced murine B16 melanoma cancer vaccine cells: induction and accumulation of cell-associated IL-15.
  • Long-term treatment of mouse cancer cells with interferon-alpha (IFN-alpha) converts parental B16 melanoma cells to B16alpha vaccine cells.
  • Inoculation of syngeneic mice with B16alpha vaccine cells triggers immunity to the parental B16 tumor that is mediated by host macrophages, T cells, and natural killer (NK) cells.
  • The release of accumulated cell-associated IL-15 may then trigger a host T cell response to tumor antigens and cause host development of immunity to the B16 tumor cells.
  • [MeSH-major] Cancer Vaccines / immunology. Interferon-alpha / physiology. Interleukin-15 / metabolism. Melanoma, Experimental / immunology. Melanoma, Experimental / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266439.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES06676; United States / NIEHS NIH HHS / ES / ES10018
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interferon-alpha; 0 / Interleukin-15
  •  go-up   go-down


92. Kim DS, Jeong YM, Park IK, Hahn HG, Lee HK, Kwon SB, Jeong JH, Yang SJ, Sohn UD, Park KC: A new 2-imino-1,3-thiazoline derivative, KHG22394, inhibits melanin synthesis in mouse B16 melanoma cells. Biol Pharm Bull; 2007 Jan;30(1):180-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new 2-imino-1,3-thiazoline derivative, KHG22394, inhibits melanin synthesis in mouse B16 melanoma cells.
  • Moreover, alpha-melanocyte-stimulating hormone (alpha-MSH) is known to increase melanin biosynthesis by increasing tyrosinase production, and here, we found that alpha-MSH-induced Mitf and tyrosinase increases were inhibited in B16 melanoma cells treated with KHG22394.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Extracellular Signal-Regulated MAP Kinases / metabolism. Melanoma, Experimental. Mice. Microphthalmia-Associated Transcription Factor / metabolism. Monophenol Monooxygenase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202683.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / KHG22394; 0 / Melanins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Mitf protein, mouse; 0 / Thiazoles; EC 1.14.18.1 / Monophenol Monooxygenase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


93. Li B, Lei Z, Lichty BD, Li D, Zhang GM, Feng ZH, Wan Y, Huang B: Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells. Cancer Immunol Immunother; 2010 Feb;59(2):313-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells.
  • Here, we report that autophagy is a negative regulator of MHC-I antigen expression in B16 melanoma cells; however, in the presence of IFN-γ, it is converted to a positive regulator.
  • Using B16 melanoma mouse model, we further show that autophagy may enhance the cytolysis of CTL to melanoma cells at the early stage of melanoma, but impairs the cytolysis at the late stage.
  • [MeSH-major] Autophagy. Histocompatibility Antigens Class I / immunology. Interferon-gamma / immunology. Melanoma, Experimental / immunology. Skin Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19680649.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


94. Chen PF, Liu LM, Chen Z, Lin SY, Song WX, Xu YF: [Effects of ethanol extracts of Panax notoginseng on liver metastasis of B16 melanoma grafted in mice]. Zhong Xi Yi Jie He Xue Bao; 2006 Sep;4(5):500-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of ethanol extracts of Panax notoginseng on liver metastasis of B16 melanoma grafted in mice].
  • OBJECTIVE: To observe the effects of ethanol extracts of Panax notoginseng on the tumor and the liver metastasis in experimental mice grafted with B16 melanoma.
  • METHODS: B16 melanoma was transplanted in the spleen of C57BL/6 mice.
  • [MeSH-major] Liver Neoplasms / prevention & control. Melanoma, Experimental / pathology. Panax notoginseng / chemistry. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965745.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Interferon-alpha; 0 / Plant Extracts; 3K9958V90M / Ethanol
  •  go-up   go-down


95. Saha S, Mohanty KC, Mallick P: Gangliosides enhance migration of mouse B16-melanoma cells through artificial basement membrane alone or in presence of laminin or fibronectin. Indian J Exp Biol; 2005 Dec;43(12):1130-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gangliosides enhance migration of mouse B16-melanoma cells through artificial basement membrane alone or in presence of laminin or fibronectin.
  • The migration of B16LuF1 cells, B16-melanoma cells of lower metastatic potential to lung was enhanced through artificial basement membrane in presence of gangliosides of B16LuF1 cells as well as gangliosides of B16-melanoma cells of higher metastatic potential to lung, namely, B16LuF5 and B16LuF10 cells.
  • Thus, gangliosides of B16 melanoma cells alone or in combination with laminin or fibronectin enhanced migration of B16 melanoma cells through artificial basement membrane, suggesting possible role of tumor gangliosides during invasion of metastatic tumor cells through basement membrane of the surrounding tissues in vivo.
  • [MeSH-major] Cell Movement / physiology. Fibronectins / physiology. G(M2) Ganglioside / physiology. G(M3) Ganglioside / physiology. Laminin / physiology. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Membranes, Artificial

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359123.001).
  • [ISSN] 0019-5189
  • [Journal-full-title] Indian journal of experimental biology
  • [ISO-abbreviation] Indian J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Fibronectins; 0 / G(M3) Ganglioside; 0 / Laminin; 0 / Membranes, Artificial; 19600-01-2 / G(M2) Ganglioside
  •  go-up   go-down


96. Gava B, Zorzet S, Spessotto P, Cocchietto M, Sava G: Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion. J Pharmacol Exp Ther; 2006 Apr;317(1):284-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
  • The antimetastatic ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlorouthenate (NAMI-A) is tested in the B16 melanoma model in vitro and in vivo.
  • Treatment of B6D2F1 mice carrying intra-footpad B16 melanoma with 35 mg/kg/day NAMI-A for 6 days reduces metastasis weight independently of whether NAMI-A is given before or after surgical removal of the primary tumor.
  • This work shows the selective effectiveness of NAMI-A on the metastatic melanoma and suggests that metastasis inhibition is due to the negative modulation of tumor cell invasion processes, a mechanism in which the reduction of the gelatinolitic activity of tumor cells plays a crucial role.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dimethyl Sulfoxide / analogs & derivatives. Lung Neoplasms / drug therapy. Melanoma, Experimental / drug therapy. Organometallic Compounds / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368900.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Adhesion Molecules; 0 / Organometallic Compounds; 0 / imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III); YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


97. Kushida S, Ohmae H, Kamma H, Totsuka R, Matsumura M, Takeuchi A, Saiki I, Yanagawa T, Onizawa K, Ishii T, Ohn T: Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with lewis lung carcinoma and B16 melanoma cells. Int J Hyperthermia; 2006 Dec;22(8):699-712

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with lewis lung carcinoma and B16 melanoma cells.
  • These cytokines in a proper combination augmented the anti-tumor effect of LH and prolonged survival time in Lewis lung carcinoma or B16 melanoma significantly.
  • Moreover, the 12-cytokine cocktail suppressed B 16 metastasis to the lung and lymph nodes, and complete regression of the tumors without regrowth occurred in 3 of 5 mice.
  • In the cured three B16 mice, there was hyperplasia of lymphatic organs with many CD3-positive T lymphocytes.
  • [MeSH-major] Carcinoma, Lewis Lung / therapy. Cytokines / therapeutic use. Hyperthermia, Induced. Immunotherapy, Active / methods. Melanoma, Experimental / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390999.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


98. Wang P, Wu P, Zhang J, Sato T, Yamagata S, Yamagata T: Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells. Biochem Biophys Res Commun; 2007 May 4;356(2):438-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.
  • However, we found that GM3 and TNFalpha were expressed in parallel in mouse melanoma B16 cells that were transfected with UDP-Gal:glucosylceramide beta-1,4-galactosyltransferase cDNA in a sense or antisense direction or CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase siRNA.
  • TNFalpha expression was increased by addition of GM3 to the B16 transfectants and decreased after treatment with D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis.
  • These results clearly indicate that GM3 positively regulates TNFalpha expression in B16 cells.
  • GM3 was shown to increase phosphorylation of Akt in B16 cells and the B16-derived transfectants.
  • Treatment of B16 cells with siRNA targeted to Akt1/2 resulted in TNFalpha suppression, indicating that Akt plays an important role in regulation of TNFalpha expression.
  • [MeSH-major] G(M3) Ganglioside / pharmacology. Melanoma / pathology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / physiology. Skin Neoplasms / pathology. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367758.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Chromones; 0 / G(M3) Ganglioside; 0 / Morpholines; 0 / Piperazines; 0 / Tumor Necrosis Factor-alpha; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 154447-38-8 / LY 303511; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; XVA4O219QW / wortmannin
  •  go-up   go-down


99. Shin JH, Choi GS, Kang WH, Myung KB: Sphingosine 1-phosphate triggers apoptotic signal for B16 melanoma cells via ERK and caspase activation. J Korean Med Sci; 2007 Apr;22(2):298-304
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphingosine 1-phosphate triggers apoptotic signal for B16 melanoma cells via ERK and caspase activation.
  • In this study, we investigated the effects of S1P on the cell growth, melanogenesis, and apoptosis of cultured B16 mouse melanoma cells.
  • In results, S1P was found to induce apoptosis in B16 melanoma cells in a dose- and time-dependent manner, but exerted minimal effects on melanogenesis.
  • Although receptors of sphingosine 1-phosphate (endothelial differentiation gene 1 [Edg]/S1P(1), Edg5/S1P(2), Edg3/S1P(3)) were expressed in B16 melanoma cells, they were shown not to be associated with S1P-induced apoptosis.
  • In addition, pertussis toxin did not block the apoptotic effects of S1P on B16 melanoma cells.
  • Interestingly, the ERK pathway inhibitor, UO126, reversed the apoptotic effects of S1P on B16 melanoma cells.
  • These results suggest that S1P induced apoptosis of B16 melanoma cells via an Edg receptor-independent, pertussis toxin-insensitive pathway, and appears to be associated with the ERK and caspase-3 activation.
  • [MeSH-major] Apoptosis / drug effects. Caspase 3 / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Lysophospholipids / administration & dosage. Melanoma / enzymology. Melanoma / pathology. Sphingosine / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1999 Nov 5;460(3):513-8 [10556527.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:147-57 [9893266.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):12200-6 [10766856.001]
  • [Cites] FEBS Lett. 2000 Jun 30;476(1-2):55-7 [10878250.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):118-23 [10913597.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34628-33 [10942778.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):385-402 [10880336.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:507-34 [11264467.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):358-63 [11284453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74 [11504919.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12724-34 [11821388.001]
  • [Cites] Pharmacol Rev. 2002 Jun;54(2):265-9 [12037142.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):25851-4 [12011102.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):37323-30 [12138095.001]
  • [Cites] Cell Signal. 2003 Oct;15(10):919-26 [12873705.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40330-6 [12835323.001]
  • [Cites] Prog Lipid Res. 1995;34(2):151-84 [7480064.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Dec 4;229(1):11-5 [8954076.001]
  • [Cites] J Biochem. 1997 May;121(5):969-73 [9192741.001]
  • [Cites] Biochem J. 1998 Mar 1;330 ( Pt 2):605-9 [9480864.001]
  • [Cites] Science. 1998 Mar 6;279(5356):1552-5 [9488656.001]
  • [Cites] J Cell Biol. 1998 Jul 13;142(1):229-40 [9660876.001]
  • [Cites] Ann N Y Acad Sci. 1998 Jun 19;845:11-8 [9668339.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27104-10 [9765227.001]
  • [Cites] FASEB J. 1998 Dec;12(15):1589-98 [9837849.001]
  • [Cites] Biochem J. 1999 Jan 1;337 ( Pt 1):67-75 [9854026.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4626-32 [9988698.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 24;260(1):203-8 [10381367.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):178-87 [15637591.001]
  • [Cites] Biochem J. 2005 Apr 15;387(Pt 2):281-93 [15801912.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Apr;290(4):C1000-8 [16267108.001]
  • [Cites] Apoptosis. 2006 Mar;11(3):337-46 [16538383.001]
  • [Cites] Neuroscience. 1999;94(2):405-15 [10579204.001]
  • (PMID = 17449940.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Lysophospholipids; 26993-30-6 / sphingosine 1-phosphate; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.22.- / Caspase 3; NGZ37HRE42 / Sphingosine
  • [Other-IDs] NLM/ PMC2693598
  •  go-up   go-down


100. Tai SS, Lin CG, Wu MH, Chang TS: Evaluation of depigmenting activity by 8-hydroxydaidzein in mouse B16 melanoma cells and human volunteers. Int J Mol Sci; 2009 Oct;10(10):4257-66
Hazardous Substances Data Bank. L-Ascorbic Acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of depigmenting activity by 8-hydroxydaidzein in mouse B16 melanoma cells and human volunteers.
  • In this study, the compound was evaluated for in vitro cellular tyrosinase and melanogenesis inhibitory activities in mouse B16 melanoma cells and for in vivo skin-whitening activity in human volunteers.
  • Hence, 8-OHDe exhibited more than an inhibitory effects on melanin production in B16 cells 10-fold stronger than kojic acid.
  • From the results of the study, it was concluded that 8-OHDe, the potent suicide substrate of mushroom tyrosinase, has depigmenting activities in both mouse melanoma cells and in human volunteers.
  • [MeSH-minor] Adult. Animals. Ascorbic Acid / analogs & derivatives. Ascorbic Acid / chemistry. Ascorbic Acid / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Female. Healthy Volunteers. Humans. Melanins / metabolism. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Mice. Middle Aged. Monophenol Monooxygenase / antagonists & inhibitors. Monophenol Monooxygenase / metabolism

  • Hazardous Substances Data Bank. Sodium ascorbate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Regul Toxicol Pharmacol. 2001 Feb;33(1):80-101 [11259181.001]
  • [Cites] Skin Res Technol. 2009 May;15(2):218-23 [19622131.001]
  • [Cites] J Am Acad Dermatol. 1996 Jan;34(1):29-33 [8543691.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 1998 Jun;44(3):345-59 [9742456.001]
  • [Cites] Biosci Biotechnol Biochem. 2005 Oct;69(10):1999-2001 [16244458.001]
  • [Cites] Dermatol Surg. 2006 Mar;32(3):372-5; discussion 375 [16640681.001]
  • [Cites] J Agric Food Chem. 2007 Mar 7;55(5):2010-5 [17295516.001]
  • [Cites] Biosci Biotechnol Biochem. 2007 May;71(5):1330-3 [17485838.001]
  • [Cites] Tohoku J Exp Med. 2007 Aug;212(4):341-8 [17660699.001]
  • [Cites] Pak J Pharm Sci. 2008 Jan;21(1):45-50 [18166519.001]
  • [Cites] Exp Dermatol. 2008 May;17(5):395-404 [18177348.001]
  • [Cites] J Periodontol. 2009 Feb;80(2):317-23 [19186973.001]
  • [Cites] Int J Mol Sci. 2009 Jun;10(6):2440-75 [19582213.001]
  • [Cites] J Cosmet Sci. 2009 May-Jun;60(3):347-52 [19586602.001]
  • [Cites] J Cosmet Sci. 2009 May-Jun;60(3):353-7 [19586603.001]
  • [Cites] Skin Pharmacol. 1994;7(3):145-50 [8003336.001]
  • (PMID = 20057943.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 8-hydroxydaidzein; 0 / Isoflavones; 0 / Melanins; 0 / Skin Lightening Preparations; 2V52R0NHXW / ascorbic acid 2-O-glucoside; EC 1.14.18.1 / Monophenol Monooxygenase; PQ6CK8PD0R / Ascorbic Acid
  • [Other-IDs] NLM/ PMC2790106
  • [Keywords] NOTNLM ; 8-hydroxydaidzein / skin whitening / suicide substrate / tyrosinase inhibitor
  • [General-notes] NLM/ Original DateCompleted: 20100628
  •  go-up   go-down






Advertisement